# DHS SCIENCE AND TECHNOLOGY

Master Question List for COVID-19 (caused by SARS-CoV-2)

# Weekly Report

14 April 2020

For comments or questions related to the contents of this document, please contact the DHS S&T Hazard Awareness & Characterization Technology Center at HACTechnologyCenter@hq.dhs.gov.



Science and Technology

DHS Science and Technology Directorate | MOBILIZING INNOVATION FOR A SECURE WORLD

**CLEARED FOR PUBLIC RELEASE** 

#### FOREWORD

The Department of Homeland Security (DHS) is paying close attention to the evolving Coronavirus Infectious Disease (COVID-19) situation in order to protect our nation. DHS is working very closely with the Centers for Disease Control and Prevention (CDC), other federal agencies, and public health officials to implement public health control measures related to travelers and materials crossing our borders from the affected regions.

Based on the response to a similar product generated in 2014 in response to the Ebolavirus outbreak in West Africa, the DHS Science and Technology Directorate (DHS S&T) developed the following "master question list" that quickly summarizes what is known, what additional information is needed, and who may be working to address such fundamental questions as, "What is the infectious dose?" and "How long does the virus persist in the environment?" The Master Question List (MQL) is intended to quickly present the current state of available information to government decision makers in the operational response to COVID-19 and allow structured and scientifically guided discussions across the federal government without burdening them with the need to review scientific reports, and to prevent duplication of efforts by highlighting and coordinating research.

The information contained in the following table has been assembled and evaluated by experts from publicly available sources to include reports and articles found in scientific and technical journals, selected sources on the internet, and various media reports. It is intended to serve as a "quick reference" tool and should not be regarded as comprehensive source of information, nor as necessarily representing the official policies, either expressed or implied, of the DHS or the U.S. Government. DHS does not endorse any products or commercial services mentioned in this document. All sources of the information provided are cited so that individual users of this document may independently evaluate the source of that information and its suitability for any particular use. This document is a "living document" that will be updated as needed when new information becomes available.

# **Table of Contents**

<ul> <li>Infectious Dose – How much agent will make a healthy individual ill?</li> <li>The human infectious dose of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is unknown by all exposure routes. SARS-CoV-2 is the cause of coronavirus disease 19 (COVID-19).</li> <li>Identifying the infectious dose for humans by any exposure route is critical to diagnostics, decontamination, and model development. Animal studies are a plausible surrogate.</li> </ul>
Transmissibility – How does it spread from one bost to another? How easily is it spread?
SARS-CoV-2 is passed easily between humans, likely through close contact with relatively large droplets and possibly through smaller aerosolized particles.
Individuals can transmit SARS-CoV-2 to others before they have symptoms. Undetected cases play a major role in transmission.
Identifying the contribution of asymptomatic or pre-symptomatic transmission is important for implementing control measures. Additionally, the relative contribution of different infection sources – fomites, droplets, aerosols, and potentially
feces – are unknown.
Host Range – How many species does it infect? Can it transfer from species to species?
SARS-CoV-2 is closely related to other coronaviruses circulating in bats in Southeast Asia. Previous coronaviruses have passed through an intermediate mammal host before infecting humans. The identity of the SARS-CoV-2 intermediate host is unknown.
SARS-CoV-2 uses the same receptor for cell entry as the SARS-CoV-1 coronavirus that circulated in 2002/2003. To date, ferrets, hamsters, cats, and primates have been shown to be susceptible to SARS-CoV-2 infection. Cats can transmit infection to other cats. It is unknown whether these animals can transmit infection to humans. Several animal models have been developed to recreate human-like illness, though to date they have been infected with
high dose exposures. Lower dose studies may better replicate human disease acquisition.
Incubation Period – How long after infection do symptoms appear? Are people infectious during this time?
after symptoms. Additionally, the possibility of reinfection warrants more research.
Clinical Presentation – What are the signs and symptoms of an infected person?
Most COVID-19 cases are mild, but severe disease can be found in any age group. Older individuals and those with underlying medical conditions are at higher risk of serious illness and death.
Current modeling suggests the overall case fatality rate (CFR) of COVID-19 is approximately 2.4%, <sup>17</sup> but varies substantially by patient age and underlying comorbidities.
Evidence suggests that African Americans are at elevated risk of severe symptoms. Additional data on vulnerable subpopulations is needed.
Children of all ages are susceptible to COVID-19, <sup>84</sup> though generally show milder <sup>55, 145</sup> or no symptoms <u>.</u>
The true case fatality rate is unknown, as the exact number of cases is uncertain. Testing priorities and case definitions vary by location.
Protective Immunity – How long does the immune response provide protection from reinfection?
Infected patients show productive immune responses, however, more data is needed.
Currently, there is no evidence that recovered patients can be reinfected with SARS-CoV-2.
Understanding the duration of protective immunity is limited by small sample sizes. Animal models are plausible surrogates.
Additional research to quantify the risk of reinfection after weeks, months, and years is needed.
Clinical Diagnosis – Are there tools to diagnose infected individuals? When during infection are they effective?
Diagnosis relies on identifying the genetic signature of the virus in patient nose, throat, or sputum samples. These tests are relatively accurate. Confirmed cases are still underreported.
Validated serological (antibody) assays are being developed to help determine who has been exposed to SARS-CoV-2.

In general, PCR tests appear to be sensitive and specific, though robust estimates of false positive/negative rates are still lacking. The efficacy of serological testing should be confirmed. Pharmaceutical Interventions – Are there effective treatments? Vaccines?......10 Treatment for COVID-19 is primarily supportive care including ventilation if necessary.<sup>100, 151</sup> Over 332<sup>4</sup> clinical trials are ongoing, but results are preliminary.<sup>65,28</sup> Convalescent sera is being tested at multiple sites across the US.<sup>152</sup> Work is ongoing to develop a SARS-CoV-2 vaccine in human and animal trials. No preliminary results are available. In general, the efficacy of various therapeutic options for COVID-19 is unknown, though clinical trial results are beginning to be released. Non-pharmaceutical Interventions – Are public health control measures effective at reducing spread?......11 Broad-scale control measures such as stay-at-home orders are effective at reducing movement, and modeling shows evidence that they reduce transmission. The effect of relaxing control measures is unknown, and research is needed to help plan for easing of restrictions. As US states have implemented differing control measures at various times, a comprehensive analysis of social distancing efficacy has not yet been conducted. SARS-CoV-2 can persist on surfaces for at least 3 days and on the surface of a surgical mask for up to 7 days depending on conditions. If aerosolized intentionally, SARS-CoV-2 is stable for at least several hours. The seasonality of COVID-19 transmission is unknown. Additional testing on SARS-CoV-2, as opposed to surrogate viruses, is needed to support initial estimates of stability. Soap and water, as well as common alcohol and chlorine-based cleaners, hand sanitizers, and disinfectants are effective at inactivating SARS-CoV-2 on hands and surfaces. Methods for decontaminating N95 masks have been approved by the FDA under Emergency Use Authorization (EUA). Additional decontamination studies, particularly with regard to PPE and other items in short supply, are needed. PPE – What PPE is effective, and who should be using it?.....14 The effectiveness of PPE for SARS-CoV-2 is currently unknown, and data from other related coronaviruses are used for guidance. Healthcare workers are at high risk of acquiring COVID-19, even with recommended PPE. Most PPE recommendations have not been made on SARS-CoV-2 data, and comparative efficacy of different PPE for different tasks (e.g., intubation) is unknown. Identification of efficacious PPE for healthcare worker is critical due to their high rates of infection. All current evidence supports the natural emergence of SARS-CoV-2 via a bat and possible intermediate mammal species. Identifying the intermediate species between bats and humans would aid in reducing potential spillover from a natural source. Current evidence suggests that SARS-CoV-2 accumulates substitutions and mutations at a similar rate as other coronaviruses. Mutations and deletions in specific portions of the SARS-CoV-2 genome have not been linked to any changes in transmission or disease severity, though modeling work is attempting to identify possible changes. Research linking genetic changes to differences in phenotype (e.g., transmissibility, virulence, progression in patients) is needed.

SARS-CoV-2 (COVID-19)	Infectious Dose – How much agent will make a healthy individual ill?
What do we know?	<ul> <li>The human infectious dose of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is unknown by all exposure routes. SARS-CoV-2 is the cause of coronavirus disease 19 (COVID-19). Work using SARS-CoV-2</li> <li>A total dose of approximately 700,000 plaque-forming units (PFU) of the novel coronavirus SARS-CoV-2 infected cynomolgus macaques via combination intranasal and intratracheal exposure (10<sup>6</sup> TCID<sub>50</sub> total dose).<sup>185</sup> Macaques did not exhibit clinical symptoms, but virus was shed from the nose and throat.<sup>185</sup></li> <li>Rhesus macaques are effectively infected with SARS-CoV-2 via the ocular conjunctival and intratracheal route at a dose of approximately 700,000 PFU (10<sup>6</sup> TCID<sub>50</sub>).<sup>81,82</sup></li> <li>Rhesus macaques infected with 2,600,000 TCID<sub>50</sub> of SARS-CoV-2 by the intranasal, intratracheal, oral and ocular routes combined recapitulate moderate disease observed in the majority of human cases.<sup>157</sup></li> <li>Ferrets infected with 316,000 TCID<sub>50</sub> of SARS-CoV-2 by the intranasal route show similar symptoms to human disease. Uninfected ferrets in direct contact with infected ferrets test positive and show disease as early as 2 days post-contact. Direct contact is required to transfer infection between ferrets.<sup>118</sup></li> <li>Syrian Golden Hamsters infected with 100,000 PFU via the intranasal route closely resemble human respiratory infection. Uninfected hamsters in close contact with infected hamsters show symptoms within 4 days of exposure.<sup>51</sup></li> <li>Domestic cats exposed to 100,000 PFU of SARS-CoV-2 via the intranasal route developed severe pathological symptoms than subadults.<sup>197</sup></li> <li>Related Coronaviruses</li> <li>The infectious dose for severe acute respiratory syndrome coronavirus 1 (SARS) in mice is estimated to be between 67-540 PFU (average 240 PFU, intranasal route).<sup>78,80</sup></li> <li>Genetically modified mice exposed intranasally to doses of Middle East respiratory syndrome coronavirus (MERS) virus between 100 and 500,000 PFU show sign</li></ul>
What do we need to know?	Identifying the infectious dose for humans by any exposure route is critical to diagnostics,         decontamination, and model development. Animal studies are a plausible surrogate.         • Human infectious dose by aerosol route         • Human infectious dose by surface contact (fomite)         • Human infectious dose by fecal-oral route

SARS-CoV-2 (COVID-19)	Transmissibility – How does it spread from one host to another? How easily is it spread?
What do we know?	<ul> <li>SARS-CoV-2 is passed easily between humans, likely through close contact with relatively large droplets and possibly through smaller aerosolized particles.</li> <li>Pandemic COVID-19 has caused 1,945,055 infections and 121,897 deaths<sup>112</sup> in at least 185 countries and territories (as of 4/14/2020).<sup>42, 192, 226</sup></li> <li>In the US there are 584,073 confirmed SARS-CoV-2 cases across all 50 US states, with 23,709 deaths (as of 4/14/2020).<sup>42, 192, 226</sup></li> <li>In the US there are 584,073 confirmed SARS-CoV-2 cases across all 50 US states, with 23,709 deaths (as of 4/14/2020).<sup>412</sup> Sustained community transmission of COVID-19 is occurring in the US.<sup>26</sup></li> <li>High-quality estimates of human transmissibility (R<sub>0</sub>) range from 2.2 to 3.1.<sup>148, 169, 182, 233, 245</sup></li> <li>SARS-CoV-2 is believed to spread through close contact and droplet transmission,<sup>46</sup> with fomite transmission likely<sup>113</sup> and close-contact aerosol transmission plausible<sup>33, 99</sup> but unconfirmed.<sup>225</sup></li> <li>Aerosolized virus has been detected in COVID-19 patient rooms, with particle sizes within the human respirable range (0.25 – 2.5 µm).<sup>141</sup></li> <li>Extensive contamination of patient rooms indicates the potential for airborne transmission, though to date infectious virus has not been isolated from aerosol samples.<sup>189</sup></li> <li>Limited evidence suggests that SARS-CoV-2 may be spread by conversation and exhalation in the absence of cough, however more work is needed.<sup>7, 189</sup> 11,<sup>130</sup></li> <li>SARS-CoV-2 replicates in the upper respiratory tract (e.g., throat), and infectious virus is detectable in throat and lung tissue for at least 8 days.<sup>228</sup></li> <li>Pre-symptomatic<sup>248</sup> or asymptomatic<sup>219</sup> patients can transmit SARS-CoV-2; between 12%<sup>85</sup> and 23%<sup>440</sup> of infections may be caused by asymptomatic or pre-symptomatic transmission. Individuals may be infectious for 1-3 days prior to symptom onset.<sup>219</sup></li> <li>Severe cases are more likely to transmit disease, and most new infection</li></ul>
What do we need to know?	<ul> <li>Identifying the contribution of asymptomatic or pre-symptomatic transmission is important for implementing control measures. Additionally, the relative contribution of different infection sources – fomites, droplets, aerosols, and potentially feces – are unknown.</li> <li>Capability of SARS-CoV-2 to be transmitted by contact with fomites (phones, doorknobs, surfaces, clothing, etc.) – see also Experimental Stability</li> <li>Superspreading capacity needs to be refined.</li> <li>Updated person to person transmission rates (e.g., R<sub>0</sub>) as control measures take effect.</li> <li>What is the underreporting rate?<sup>110</sup></li> <li>Can individuals become re-infected with SARS-CoV-2?</li> <li>What is the difference in transmissibility among countries?</li> <li>Is the R<sub>0</sub> estimate higher in healthcare or long-term care facilities?</li> <li>How effective are social distancing measures?</li> <li>When will infections peak in various cities and countries?</li> </ul>

SARS-Cov-2 (COVID-19)	Host Range – How many species does it infect? Can it transfer from species to species?
What do we know?	<ul> <li>SARS-CoV-2 is closely related to other coronaviruses circulating in bats in Southeast Asia. Previous coronaviruses have passed through an intermediate mammal host before infecting humans. The identity of the SARS-CoV-2 intermediate host is unknown.</li> <li>Early genomic analysis indicates similarity to SARS-CoV-1,<sup>251</sup> with a suggested bat origin,<sup>5,67,251</sup></li> <li>Positive samples from the South China Seafood Market strongly suggests a wildlife source,<sup>48</sup> though it is possible that the virus was circulating in humans before the disease was associated with the seafood market,<sup>27,69,236,243</sup></li> <li>Analysis of SARS-CoV-2 genomes suggests that a non-bat intermediate species is responsible for the beginning of the outbreak.<sup>184</sup> The identity of the intermediate host remains unknown,<sup>1134,137-138</sup></li> <li>Viruses similar to SARS-CoV-2 were present in pangolin samples collected several years ago.<sup>123</sup></li> <li>SARS-CoV-2 uses the same receptor for cell entry as the SARS-CoV-1 coronavirus that circulated in 2002/2003.</li> <li>Experiments show that SARS-CoV-2 Spike (S) receptor-binding domain binds the human cell receptor (ACE2) stronger than SARS-CoV-1,<sup>231</sup> potentially explaining its high transmissibility. The same work suggests that differences between SARS-CoV-2 and SARS-CoV-1 can bind and infect human, bat, civet, monkey and swine cells.<sup>213</sup></li> <li>Modeling of SARS-CoV-2 Spike and ACE2 proteins suggests that SARS-CoV-2 can bind and infect human, bat, civet, monkey and swine cells.<sup>213</sup></li> <li>Receptor binding is not the only feature of coronaviruses that facilitate cell entry, however, changes in proteolytic cleavage of Spike protein can also affect animal host range.<sup>153</sup></li> <li>To date, ferrets, hamsters, cats, and primates have been shown to be susceptible to SARS-CoV-2 infection. Cats can transmit infection to other cats. It is unknown whether these animals can transmit infection to humans.</li> <li>Animal model studies suggest that Golden Syrian hamsters, primates and ferrets may be su</li></ul>
What do we need to know?	<ul> <li>that SARS-CoV-2 infects livestock.<sup>109</sup></li> <li>Several animal models have been developed to recreate human-like illness, though to date they have been infected with high dose exposures. Lower dose studies may better replicate human disease acquisition.</li> <li>What is the intermediate host(s)?</li> <li>What are the mutations in SARS-CoV-2 that allowed human infection and transmission?</li> <li>What other animals can SARS-CoV-2 infect (e.g., pet dogs, potential wildlife reservoirs)?</li> <li>Can infected animals transmit to humans (e.g., pet cats, pet dogs to humans)?</li> </ul>

SARS-CoV-2 (COVID-19)	Incubation period – How long after infection do symptoms appear? Are people infectious during this time?
What do we know?	<ul> <li>The majority of individuals develop symptoms within 14 days of exposure. For most people, it takes at least 2 days to develop symptoms, and on average symptoms develop 5 days after exposure. Some individuals never develop symptoms but can still transmit disease.</li> <li>The best current estimate of the COVID-19 incubation period is 5.1 days, with 99% of individuals exhibiting symptoms within 14 days of exposure.<sup>126</sup> Fewer than 2.5% of infected individuals show symptoms sooner than 2 days after exposure.<sup>126</sup></li> <li>Individuals can test positive for COVID-19 even if they lack clinical symptoms.<sup>21, 50, 100, 203, 248</sup></li> <li>Individuals can be infectious while asymptomatic,<sup>46, 186, 203, 248</sup> and asymptomatic individuals can have similar amounts of virus in their nose and throat as symptomatic individuals.<sup>253</sup></li> <li>Infectious period is unknown, but possibly up to 10-14 days.<sup>10, 133, 192</sup></li> <li>On average, there are approximately 4<sup>85</sup> to 7.5<sup>132</sup> days between symptom onset in successive cases of a single transmission chain.</li> <li>Most hospitalized individuals are admitted within 8-14 days of symptom onset.<sup>250</sup></li> </ul>
What do we need to know?	<ul> <li>While the incubation period is well-characterized, less is known about how long individuals are infectious before, during, and after symptoms. Additionally, the possibility of reinfection warrants more research.</li> <li>What is the average infectious period during which individuals can transmit the disease?</li> <li>Are individuals infectious after hospital discharge and clinical recovery, or are positive PCR tests only detecting non-infectious virus?</li> <li>Can individuals become re-infected after recovery? If so, how long after?</li> </ul>

SARS-CoV-2 (COVID-19)	Clinical presentation – What are the signs and symptoms of an infected person?
What do we know?	<ul> <li>Most COVID-19 cases are mild, but severe disease can be found in any age group. Older individuals and those with underlying medical conditions are at higher risk of serious illness and death.</li> <li>The majority of COVID-19 cases are mild (81%, N = 44,000 cases).<sup>203</sup></li> <li>Initial COVID-19 symptoms include fever (87.9% overall, but only 44% - 52% present with fever initially<sup>48,100</sup>, cough (67.7%<sup>100</sup>), fatigue, shortness of breath, headache, and reduced lymphocyte count.<sup>47,54,107</sup> Headache<sup>53</sup> is uncommon. Diarrhea may be uncommon.<sup>107,132</sup> though lack of appetite may be an early symptom.<sup>167</sup></li> <li>Complications include acute respiratory distress (ARDS), 17-29% of hospitalized patients, <sup>58,107</sup> leading to death in 4.15% of cases<sup>58,107,214</sup>), pneumonia.<sup>166</sup> cardiac injury (20%<sup>138</sup>), secondary infection, kidney failure, arrhythmia, sepsis, and shock.<sup>100,107,214,250</sup></li> <li>Most deaths are caused by respiratory failure or respiratory failure combined with myocardial (heart) damage.<sup>187</sup></li> <li>Approximately 15% of hospitalized patients are classified as severe,<sup>100,203</sup> and approximately 5% of patients are admitted to the ICU.<sup>100,203</sup></li> <li>Loss of taste and smell appears in 5-30% of patients who test positive, however ~18% of individuals who test negative also report this symptom. More work is needed.<sup>20,56,33</sup></li> <li>Several studies suggest that SARS-COV-2 is not transmitted from mother to child during birth,<sup>57,59,193,240</sup> however larger studies are needed.</li> <li>Ocular symptoms such as conjunctivitis have been seen in severe COVID-19 cases.<sup>235</sup></li> <li>Current modeling suggests the overall case fatality rate (CFR) of COVID-19 is approximately 2.4%,<sup>17</sup> but varies substantially by patient age and underlying comorbidities.</li> <li>The CFR depends on comorbidities. Cardiovascular disease, hypertension, diabetes, and respiratory conditions all increase the CFR.<sup>203,250</sup></li> <li>The CFR depends on comorbidities. Cardiovascula</li></ul>
What do we need to know?	<ul> <li>The true case fatality rate is unknown, as the exact number of cases is uncertain. Testing priorities and case definitions vary by location.</li> <li>How long does it take for infected individuals to recover outside of a healthcare setting?</li> <li>Are reductions in CFR over time (e.g., China) an indication of better treatment, less overcrowding, or both?</li> <li>Are pregnant women at greater risk of complications during labor?<sup>136</sup></li> <li>How prevalent is loss of smell, loss of taste and gastrointestinal symptoms in COVID-19 patients?</li> </ul>

SARS-CoV-2 (COVID-19)	Protective Immunity – How long does the immune response provide protection from reinfection?
What do we know?	<ul> <li>Infected patients show productive immune responses, however more data is needed.</li> <li>In a limited study (n=9), hospitalized patients shed high levels of infectious virus for 7-days via the nasal- pharyngeal route, 50% of patients seroconverted within 7 days, and all patients by 14 days. Seroconversion did not correlate with lower viral load.<sup>228</sup></li> <li>In a larger study (n=175), most patients developed neutralizing antibodies within 10-15 days after disease onset. Elderly patients had significantly higher neutralizing antibody titers than younger patients.<sup>232</sup></li> <li>Based on one patient, a productive immune response is generated and sustained for at least 7 days.<sup>204</sup> Previous studies on coronavirus immunity suggest that neutralizing antibody may wane after several years. <sup>36,234</sup> More data are needed.</li> <li>A small subset of COVID-19 patients in China (8%) did not develop a serological response to infection, and the potential for reinfection in these patients is unknown.<sup>232</sup> Interestingly, the majority of patients that failed to develop a quantifiable immune response were &lt; 40 years old.</li> <li>Currently, there is no evidence that recovered patients can be reinfected with SARS-CoV-2.</li> <li>Experimentally infected macaques were not capable of being reinfected after their primary infection resolved.<sup>23</sup></li> <li>According to the WHO, there is no evidence of re-infection with SARS-CoV-2 after recovery.<sup>125</sup></li> <li>Patients can test positive via PCR for up to 37 days after symptoms appear,<sup>250</sup> and after recovery and hospital discharge.<sup>124</sup> The ability of these individuals to infect others is unknown.</li> </ul>
What do we need to know?	<ul> <li>Understanding the duration of protective immunity is limited by small sample sizes. Animal models are plausible surrogates. Additional research to quantify the risk of reinfection after weeks, months, and years is needed.</li> <li>How long does the immune response last?</li> <li>Is there evidence of waning immunity?</li> <li>Can humans become reinfected?</li> <li>Are patients who test positive weeks after discharge from hospital capable of transmitting infection?</li> <li>How does the patient immune response vary by age?</li> </ul>

SARS-CoV-2 (COVID-19)	Clinical Diagnosis – Are there tools to diagnose infected individuals? When during infection are they effective?
What do we know?	<ul> <li>Diagnosis relies on identifying the genetic signature of the virus in patient nose, throat, or sputum samples. These tests are relatively accurate. Confirmed cases are still underreported.</li> <li>US CDC has expanded patient testing criteria to include symptomatic patients at clinician discretion.<sup>23</sup></li> <li>PCR protocols and primers have been widely shared internationally.<sup>41,71,132,196,222,227</sup> PCR-based diagnostic assays are unable to differentiate between active and inactive virus.</li> <li>Broad testing in Iceland suggests that ~50% of those who test positive are symptom-free at the time of testing.<sup>19 155</sup></li> <li>A combination of pharyngeal (throat) RT-PCR and chest tomography are the most effective diagnostic criteria (correctly diagnose 91.9% of infections).<sup>179</sup> A single throat swab detects 78.2% of infections, and uplicate tests identify 86.2% of infections.<sup>179</sup></li> <li>Nasal and upharyngeal swabs may be less effective as diagnostic specimens than sputum and bronchoalveolar lavage fluid.<sup>215</sup> although recent evidence suggests this may not always be the case.<sup>228</sup> More work is needed.</li> <li>RT-PCR tests can identify asymptomatic cases. The SARS-CoV-2 infection was identified in 2/114 individuals cleared by clinical assessment.<sup>106</sup></li> <li>Combination RT-PCR and serology (antibody) testing may increase the ability to diagnose patients with mild symptoms, or identify patients at higher risk of severe disease.<sup>247</sup></li> <li>The FDA released an Emergency Use Authorization enabling laboratories to develop and use tests in-house for patient diagnosis.<sup>93</sup></li> <li>Updated tests from the US CDC are available to states.<sup>41,46</sup></li> <li>Multiple rapid or real-time test kits have been produced by universities and industry, including the Wuhan institute of Virology.<sup>74</sup> BG1,<sup>30</sup> Cepheid<sup>212</sup>, Abbot,<sup>94</sup> and Mesa Biotech.<sup>30</sup></li> <li>The US CDC is developing serological tests to determine what proportion of the population has been exposed to SARS-COV-2.<sup>116</sup> A rapid antibody test by Cellex is</li></ul>
What do we need to know?	<ul> <li>In general, PCR tests appear to be sensitive and specific, though robust estimates of false positive/negative rates are still lacking. The efficacy of serological testing should be confirmed.</li> <li>False positive/negative rates for tests</li> <li>Eclipse phase of infection (time between infection and detectable disease) in an individual</li> <li>With limited testing in many locations, how accurate are clinical diagnoses compared to genetic tests?</li> <li>How effective are different swab specimens as diagnostic samples?</li> <li>How many serological tests need to be done to obtain an accurate picture of underlying exposure?</li> </ul>

SARS-CoV-2 (COVID-19)	Pharmaceutical Interventions – Are there effective treatments? Vaccines?
What do we know?	<ul> <li>Treatment for COVID-19 is primarily supportive care including ventilation if necessary.<sup>100, 151</sup> Over 332<sup>4</sup> clinical trials are ongoing, but results are preliminary.<sup>65,28</sup> Convalescent sera is being tested at multiple sites across the US.<sup>152</sup></li> <li>WHO is tracking &gt;50 potential vaccines.<sup>68</sup> and has begun two global clinical trials: Solidarity and Discovery <sup>121</sup>that include remdesivir, hydroxychloroquine and chloroquine, ritonavir/lopinavir, and ritonavir/lopinavir and interferon-beta.<sup>121</sup></li> <li>Limited, preliminary evidence from clinical trials supports the efficacy of favipiravir,<sup>56</sup> tocilizumab,<sup>237</sup> intravenous immunoglobulin,<sup>38</sup> and hydroxychloroquine with azithromycin.<sup>97, 142</sup> Additional work including sufficiently powered clinical trials are necessary to confirm therapeutic efficacy of any of these compounds.</li> <li>Limited, preliminary evidence shows mixed efficacy of chloroquine alone,<sup>3</sup> and no efficacy from combination ritonavir and lopinavir.<sup>37</sup> Additional work is necessary to confirm these results.</li> <li>Favipiravir has been approved to treat COVID-19 in China.<sup>1</sup></li> <li>Antibody based therapeutics are planned to start clinical trials in 3-5 months.<sup>64, 89, 202</sup></li> <li>Teams across the USA are testing passive antibody therapy (convalescent serum<sup>39</sup>) to patients (FDA Investigational New Drug approval).<sup>92</sup> In a small trial (5 patients).<sup>195</sup> convalescent sera administration was followed by clinical improvement.<sup>195</sup></li> <li>Corticosteroids are commonly given to COVID-19 patients<sup>250</sup> at risk of ARDS,<sup>238</sup> but their use is not recommended by the US CDC.<sup>43</sup></li> <li>Laboratory testing identified 17 repurposed drugs and remdesivir-like nucleoside inhibitors<sup>194</sup> with significant antiviral activity, however more research is needed to confirm efficacy.<sup>220</sup></li> <li>Additional clinical trials involving anti-inflammatory drugs are recruiting patients (interleukin-6 inhibitors, sarilumab<sup>2</sup> and tocilizumab<sup>2</sup>).</li> <li>For pa</li></ul>
What do we need to know?	<ul> <li>In general, the efficacy of various therapeutic options for COVID-19 is unknown, though clinical trial results are beginning to be released.</li> <li>Is GS-5734 (remdesivir) effective in vivo (already used in clinical trials under Emergency Use Authorization)?<sup>193</sup></li> <li>Is the GLS-5000 MERS vaccine<sup>242</sup> cross-reactive against SARS-CoV-2?</li> <li>Efficacy of antibody treatments developed for SARS<sup>72, 201</sup> and MERS<sup>49</sup></li> <li>What is the efficacy of various MERS and SARS Phase I/II vaccines and other therapeutics?</li> <li>Are viral replicase inhibitors such as beta-D-N4-hydroxycytidine effective against SARS-CoV-2?<sup>24</sup></li> </ul>

SARS-CoV-2 (COVID-19)	Non-pharmaceutical Interventions – Are public health control measures effective at reducing spread?
What do we know?	<ul> <li>Broad-scale control measures such as stay-at-home orders are effective at reducing movement, and modeling shows evidence that they reduce transmission.</li> <li>Social distancing and other policies are estimated to have reduced COVID-19 spread by 44% in Hong Kong<sup>73</sup> and reduced spread in China.<sup>119,143</sup></li> <li>Modeling demonstrates that multifaceted restrictions and quarantines in China reduced the R<sub>0</sub> of SARS-CoV-2 from greater than 3 to less than 1 between January 23<sup>rd</sup> and February 5<sup>th</sup>.<sup>105</sup></li> <li>Models indicate that a combination of school closures, work restrictions, and other measures are required to effectively limit transmission.<sup>94</sup></li> <li>Preliminary modeling results from Japan suggest that school closures alone were not sufficient to limit COVID-19 spread, though the school closures in question only applied to students between 6 and 18 years of age.<sup>111</sup></li> <li>Globally, there is some evidence that implementing social distancing measures has reduced the amount individuals travel, though the data are based on planned rather than actual trips.<sup>149</sup></li> <li>Restrictive lockdowns in China are estimated to have reduced disease transmission within only a few days.<sup>252</sup></li> <li>Non-pharmaceutical interventions in China did not reduce transmission equally across all groups; transmission rates in younger individuals, particularly infants, as well as hospital workers continued to increase even while overall transmission rates declined.<sup>165</sup></li> <li>The effect of relaxing control measures is unknown, and research is needed to help plan for easing of restrictions.</li> <li>Modeling suggests that premature lifting of social distancing measures will substantially increase the number of local COVID-19 cases in Wuhan, China.<sup>170</sup></li> <li>Similarly, forecasts in the US estimate a resumption of exponential case growth if social distancing measures are put into place every few weeks to keep healthcare demand below a critical point.<sup>241</sup></li> <li>A modeling study using Chinese data estimated</li></ul>
What do we need to know?	<ul> <li>As different US states have implemented differing control measures at various times, a comprehensive analysis of social distancing efficacy has not yet been conducted.</li> <li>How many cases in the US have been averted due to social distancing restrictions?</li> <li>How long does it take for various non-pharmaceutical interventions to show effects?</li> <li>What are effective surrogate measures of social distancing efficacy (e.g., reduction in travel, contact, traffic, etc.)?</li> <li>What are plausible options for relaxing social distancing and other intervention measures without resulting in a resurgence of COVID-19 cases?</li> </ul>

SARS-CoV-2 (COVID-19)	Environmental Stability – How long does the agent live in the environment?
What do we know?	SARS-CoV-2 can persist on surfaces for at least 3 days and on the surface of a surgical mask for up to 7 days depending on conditions. If aerosolized intentionally, SARS-CoV-2 is stable for at least several hours. The seasonality of COVID-19 transmission is unknown. SARS-CoV-2 Data
	• SARS-CoV-2 can persist on plastic and metal surfaces for between 3 days (21-23°C, 40% RH) <sup>210</sup> and 7 days (22°C, 65% RH). Infectious virus can be recovered from a surgical mask after 7 days (22°C, 65% RH). <sup>61</sup>
	<ul> <li>SARS-CoV-2 has an aerosol half-life of 2.7 hours (particles &lt;5 μm, tested at 21-23°C and 65% RH).<sup>210</sup></li> <li>SARS-CoV-2 is susceptible to heat treatment (70°C), but can persist for at least two weeks at refrigerated temperatures (4°C).<sup>61, 176</sup></li> </ul>
	• SARS-CoV-2 genetic material (RNA) was detected in symptomatic and asymptomatic cruise ship passenger rooms up to 17 days after cabins were vacated. The infectiousness of this material is not known. <sup>156</sup>
	Surrogate Coronavirus data:
5	• Studies suggest that other coronaviruses can survive on non-porous surfaces up to 9-10 days (MHV, SARS-CoV), <sup>40, 52</sup> and porous surfaces for up to 3-5 days (SARS-CoV) <sup>87</sup> in air conditioned environments (20-25°C, 40-50% RH).
	• Coronavirus survival tends to be higher at lower temperatures and lower relative humidity (RH), <sup>40,</sup> <sup>52, 174, 211</sup> though infectious virus can persist on surfaces for several days in typical office or hospital conditions. <sup>211</sup>
5	• SARS can persist with trace infectivity for up to 28 days at refrigerated temperatures (4°C) on surfaces. <sup>40</sup>
	• No strong evidence exists showing reduction in transmission with seasonal increase in temperature and humidity. <sup>147</sup>
	• One hour after aerosolization approximately 63% of airborne MERS virus remained viable in a simulated office environment (25°C, 75% RH). <sup>171</sup>
	• Porous hospital materials, including paper and cotton cloth, maintain infectious SARS-CoV for a shorter time than non-porous material. <sup>122</sup>
What do we need to know?	Additional testing on SARS-CoV-2, as opposed to surrogate viruses, is needed to support initial estimates of stability.
6	<ul> <li>Stability of SARS-CoV-2 in aerosol, droplets, and other matrices (mucus/sputum, feces)</li> <li>Particle size distribution (e.g., droplet, large droplet and true aerosol distribution)</li> <li>Duration of SARS-CoV-2 infectivity via fomites and surface (contact hazard)</li> <li>Stability of SARS-CoV-2 on PPE (e.g., Tyyek, nitrile, etc.)</li> </ul>

SARS-CoV-2 (COVID-19)	Decontamination – What are effective methods to kill the agent in the environment?
What do we know?	<ul> <li>Soap and water, as well as common alcohol and chlorine-based cleaners, hand sanitizers, and disinfectants are effective at inactivating SARS-CoV-2 on hands and surfaces. <i>SARS-CoV-2</i></li> <li>Alcohol-based hand rubs are effective at inactivating SARS-CoV-2.<sup>120</sup></li> <li>Chlorine bleach (1%, 2%), 70% ethanol and 0.05% chlorhexidine are effective against live virus in lab tests.<sup>60</sup></li> <li>Twice-daily cleaning with sodium dichloroisocyanurate decontaminated surfaces in COVID-19 patient hospital rooms.<sup>163</sup></li> <li>EPA has released a list of SARS-CoV-2 disinfectants, but solutions were not tested on live virus.<sup>12</sup> <i>Other Coronaviruses</i></li> <li>Chlorine-based<sup>224</sup> and ethanol-based<sup>70</sup> solutions are recommended.</li> <li>Heat treatment (56°C) is sufficient to kill coronaviruses, <sup>174, 249</sup> though effectiveness depends partly on protein in the sample.<sup>174</sup></li> <li>70% ethanol, 50% isopropanol, sodium hypochlorite (0.02% bleach), and UV radiation can inactivate several coronaviruses (MHV and CCV).<sup>188</sup></li> <li>Ethanol-based biocides effectively disinfect coronaviruses dried on surfaces, including ethanol containing gels similar to hand sanitizer.<sup>108, 229</sup></li> <li>Surface spray disinfectants such as Mikrobac, Dismozon, and Korsolex are effective at reducing infectivity of the closely related SARS-COV after 30 minutes of contact.<sup>173</sup></li> <li>Coronaviruses may be resistant to thermal inactivation for up to 7 days when stabilized in stool.<sup>205, 206</sup></li> <li>Coronaviruses are more stable in matrixes such as respiratory sputum.<sup>86</sup></li> <li>Methods for decontaminating N95 masks have been approved by the FDA under Emergency Use Authorization from the FDA.<sup>30</sup></li> <li>The FDA has issued an Emergency Use Authorization for a system capable of decontaminating 10</li> </ul>
What do we need to know?	<ul> <li>Additional decontamination studies, particularly with regard to PPE and other items in short supply, are needed.</li> <li>What is the minimal contact time for disinfectants?</li> <li>Does contamination with human fluids/waste alter disinfectant efficacy profiles?</li> <li>How effective is air filtration at reducing transmission in healthcare, airplanes and public spaces?</li> <li>Are landfills and wastewater treatment plants effective at inactivating SARS-CoV-2?</li> <li>Is heat or UV decontamination effective to clean N95 respirators and other types of PPE for multi-use?</li> </ul>

"LA

SARS-CoV-2 (COVID-19)	PPE – What PPE is effective, and who should be using it?	
What do we know?	<ul> <li>The effectiveness of PPE for SARS-CoV-2 is currently unknown, and data from other related coronaviruses are used for guidance. Healthcare workers are at high risk of acquiring COVID-19, even with recommended PPE.</li> <li>Healthcare worker illnesses (over 1,000<sup>203</sup>) demonstrates human-to-human transmission despite isolation, PPE, and infection control.<sup>190</sup></li> <li>Risk of transmission to healthcare workers appears high, with up to 20% of healthcare workers in Lombardy, Italy becoming infected.<sup>178</sup></li> <li>"Healthcare personnel entering the room [of SARS-CoV-2 patients] should use standard precautions, contact precautions, airborne precautions, and use eye protection (e.g., goggles or a face shield)."<sup>44</sup></li> <li>WHO indicates healthcare workers should wear clean long-sleeve gowns as well as gloves.<sup>223</sup></li> <li>Respirators (NIOSH-certified N95, EUFFP2 or equivalent) are recommended for those dealing with possible aerosols.<sup>224</sup> Additional protection, such as a Powered Air Purifying Respirator (PAPR) with a full hood, should be considered for high-risk procedures (i.e., intubation, ventilation).<sup>34</sup></li> <li>Particular attention should be paid to the potential for transmission via exhaled air during supportive respiratory procedures.<sup>99</sup></li> <li>There is evidence both for<sup>141</sup> and against<sup>163</sup> the detection of SARS-CoV-2 RNA via air sampling in patient rooms and other hospital areas.</li> <li>Research at Johns Hopkins Center for Health Security has provided initial estimates of PPE needs in the US: 7.8 billion gloves, 668 million gowns, 360 million surgical masks, and 136 million N95 or similar respirators.<sup>208</sup></li> <li>Masks may be effective at slowing transmission.</li> <li>Surgical face masks, respirators and homemade face masks may prevent transmission of coronaviruses from infectious individuals (with or without symptoms) to other individuals.<sup>128, 209, 77</sup> More work is needed.</li> <li>On 4/3/2020, the US CDC recommended wearing cloth face masks in public where social distancing measures</li></ul>	
What do we need to know?	<ul> <li>Most PPE recommendations have not been made on SARS-CoV-2 data, and comparative efficacy of different PPE for different tasks (e.g., intubation) is unknown. Identification of efficacious PPE for healthcare workers is critical due to their high rates of infection.</li> <li>What is the importance of aerosol transmission? What is the effective distance of spread via droplet or aerosol?</li> <li>How effective are barriers such as N95 respirators or surgical masks?</li> <li>What is the appropriate PPE for first responders? Airport screeners?</li> <li>What are proper procedures for reducing spread and transmission rates in medical facilities?</li> <li>How effective are homemade masks at reducing transmission?</li> </ul>	
	<ul> <li>How effective are barriers such as N95 respirators or surgical masks?</li> <li>What is the appropriate PPE for first responders? Airport screeners?</li> <li>What are proper procedures for reducing spread and transmission rates in medical facilities?</li> <li>How effective are homemade masks at reducing transmission?</li> </ul>	

SARS-CoV-2 (COVID-19)	Forensics – Natural vs intentional use? Tests to be used for attribution.	
What do we know?	<ul> <li>All current evidence supports the natural emergence of SARS-CoV-2 via a bat and possible intermediate mammal species.</li> <li>Genomic analysis places SARS-CoV-2 into the beta-coronavirus clade, with close relationship to bat coronaviruses. The SARS-CoV-2 virus is distinct from SARS-CoV-1 and MERS viruses.<sup>83</sup></li> <li>Genomic analysis suggests that SARS-CoV-2 is a natural variant and is unlikely to be human-derived or otherwise created by "recombination" with other circulating strains of coronavirus.<sup>15, 251</sup></li> <li>Genomic data support at least two plausible origins of SARS-CoV-2: "(i) natural selection in a nonhuman animal host prior to zoonotic transfer, and (ii) natural selection in humans following zoonotic transfer."<sup>15</sup> Both scenarios are consistent with the observed genetic changes found in all known SARS-CoV-2 isolates.</li> <li>Some SARS-CoV-2 genomic evidence indicates a close relationship with pangolin coronaviruses,<sup>230</sup> and data suggests that pangolins may be a natural host for beta-coronaviruses.<sup>137, 138</sup> Additional research is needed.</li> <li>Additionally, "[] SARS-CoV-2 is not derived from any previously used virus backbone," reducing the likelihood of laboratory origination,<sup>15</sup> and "[] genomic evidence does not support the idea that SARS-CoV-2 is a laboratory construct, [though] it is currently impossible to prove or disprove the other theories of its origin."<sup>15</sup></li> <li>Work with other coronaviruses have indicated that heparan sulfate dependence can be an indicator of prior cell passage, due to a mutation in the previous furin enzyme recognition motif.<sup>79</sup></li> </ul>	
What do we need to know?	Identifying the intermediate species between bats and humans would aid in reducing potential spillover from a natural source.         • What tests for attribution exist for coronavirus emergence?         • What is the identity of the intermediate species?         • Are there closely related circulating coronaviruses in bats or other animals with the novel PRRA cleavage site found in SARS-CoV-2?	

SARS-CoV-2 (COVID-19)	Genomics – How does the disease agent compare to previous strains?	
What do we know?	<ul> <li>Current evidence suggests that SARS-CoV-2 accumulates substitutions and mutations at a similar rate as other coronaviruses. Mutations and deletions in specific portions of the SARS-CoV-2 genome have not been linked to any changes in transmission or disease severity, though modeling work is attempting to identify possible changes.</li> <li>There have been no documented cases of SARS-CoV-2 prior to December 2019.</li> <li>Preliminary genomic analyses, however, suggest that the first human cases of SARS-CoV-2 emerged between 10/19/2019 – 12/17/2019.<sup>16, 27, 175</sup></li> <li>The mutation rate of SARS-CoV-2 is estimated to be similar to other RNA viruses (e.g., SARS, Ebola, Zika), and is currently calculated to be 1.04x10<sup>-3</sup> substitutions per site per year (N = 116 genomes).<sup>104</sup></li> <li>Pangolin coronaviruses are closely related to both SARS-CoV-2 and closely related bat coronaviruses. Phylogenetic analysis suggests that SARS-CoV-2 is of bat origin, but is closely related to pangolin coronavirus.<sup>137-138</sup></li> <li>The SARS-CoV-2 Spike protein, which mediates entry into host cells and is the major determinant of host range, is very similar to the SARS-CoV-1 Spike protein.<sup>144</sup> The rest of the genome is more closely related to two separate bat<sup>144</sup> and pangolin<sup>138</sup> coronaviruses.</li> <li>Analysis of SARS-CoV-2 sequences from Singapore has identified a large nucleotide (382 bp) deletion in ORF-8.<sup>200</sup> The effect of this deletion on transmission or virulence is unknown.</li> <li>A recent report of virus mutations within patients needs more research.<sup>117</sup> Additional analysis of data suggests that specific changes in the genetic sequence of the SARS-CoV-2 Spike Protein may enhance binding of the virus to human ACE2 receptors.<sup>164</sup> More specifically, changes to two residues (Q493 and N501) are linked with improving the stability of the virus-receptor binding complex.<sup>164</sup></li> </ul>	
What do we need to know?	<ul> <li>Research linking genetic changes to differences in phenotype (e.g., transmissibility, virulence, progression in patients) is needed.</li> <li>Are there similar genomic differences in the progression of coronavirus strains from bat to intermediate species to human?</li> <li>Are there different strains or clades of circulating virus? If so, do they differ in virulence?</li> </ul>	

Table 1. Definitions of commonly-used acronyms

Acronym/Term	Definition	Description
ACE2	Angiotensin-converting enzyme 2	Acts as a receptor for SARS-CoV, allowing entry into human cells
Airborne transmission	Aerosolization of infectious particles	Aerosolized particles can spread for long distances (e.g., between hospital rooms via HVAC systems)
ARDS	Acute respiratory distress syndrome	Leakage of fluid into the lungs which inhibits respiration and leads to death
Attack rate	Proportion of "at-risk" individuals who develop infection	Defined in terms of "at-risk" population such as schools or households, defines the proportion of individuals in those populations who become infected after contact with an infectious individual
CCV	Canine coronavirus	Canine coronavirus
CFR	Case Fatality Rate	Number of deaths divided by confirmed patients
CoV	Coronavirus	Virus typified by crown-like structures when viewed under electron microscope
COVID-19	Coronavirus disease 19	Official name for the disease caused by the SARS-CoV-2 virus.
Droplet transmission	Sneezing, coughing	Transmission via droplets requires relatively close contact (e.g., within 6 feet)
Fomite	Inanimate vector of disease	Surfaces such as hospital beds, doorknobs, healthcare worker gowns, faucets, etc.
HCW	Healthcare worker	Doctors, nurses, technicians dealing with patients or samples
Incubation period	Time between infection and symptom onset	Time between infection and onset of symptoms typically establishes guidelines for isolating patients before transmission is possible
Infectious period	Length of time an individual can transmit infection to others	Reducing the infectious period is a key method of reducing overall transmission; hospitalization, isolation, and quarantine are all effective methods
Intranasal	Agent deposited into external nares of subject	Simulates inhalation exposure by depositing liquid solution of pathogen/virus into the nose of a test animal, where it is then taken up by the respiratory system.
MERS	Middle-East Respiratory Syndrome	Coronavirus with over 2,000 cases in regional outbreak since 2012
MHV	Mouse hepatitis virus	Coronavirus surrogate
Nosocomial	Healthcare- or hospital- associated infections	Characteristic of SARS and MERS outbreaks, lead to refinement of infection control procedures
PCR	Polymerase chain reaction	PCR (or real-time [RT] or quantitative [Q] PCR) is a method of increasing the amount of genetic material in a sample, which is then used for diagnostic testing to confirm the presence of SARS-CoV-2
PFU	Plaque forming unit	Measurement of the number of infectious virus particles as determined by plaque forming assay. A measurement of sample infectivity.
PPE	Personal protective equipment	Gowns, masks, gloves, and any other measures used to prevent spread between individuals
R <sub>0</sub>	Basic reproduction number	A measure of transmissibility. Specifically, the average number of new infections caused by a typical infectious individual in a wholly susceptible population.
SARS	Severe Acute Respiratory Syndrome	Coronavirus with over 8,000 cases in global 2002-2003 outbreak
SARS-CoV-2	Severe acute respiratory syndrome coronavirus 2	Official name for the virus previously known as 2019-nCoV.

## REQUIRED INFORMATION FOR EFFECTIVE INFECTIOUS DISEASE OUTBREAK RESPONSE SARS-CoV-2 (COVID-19) Updated 4/14/2020

Acronym/Term	Definition	Description
Serial interval	Length of time between symptom onset of successive cases in a transmission chain	The serial interval can be used to estimate $R_0$ , and is useful for estimating the rate of outbreak spread
Superspreading	One individual responsible for an abnormally large number of secondary infections	Superspreading can be caused by high variance in the distribution of secondary cases caused by a single individual; most individuals infect very few people, while some infect a large number, even with the same average number of secondary infections
TCID <sub>50</sub>	50% Tissue Culture Infectious Dose	The number of infectious units which will infect 50% of tissue culture monolayers. A measurement of sample infectivity.
Transgenic	Genetically modified	In this case, animal models modified to be more susceptible to MERS and/or SARS by adding proteins or receptors necessary for infection



#### Literature Cited:

1. (U) China approves first anti-viral drug against coronavirus Covid-19. *Pharmaceutical Technology* 2020.

2. (U) Evaluation of the Efficacy and Safety of Sarilumab in Hospitalized Patients With COVID-19. https://clinicaltrials.gov/ct2/show/NCT04315298?term=sarilumab&cond=covid&draw=2&rank=1.

3. (U) French researcher posts successful Covid-19 drug trial. Connexion: 2020.

https://www.connexionfrance.com/French-news/French-researcher-in-Marseille-posts-successful-Covid-19-coronavirus-drug-trial-results

4. (U) Global coalition to accelerate COVID-19 clinical research in resource-limited settings. *The Lancet*. https://doi.org/10.1016/S0140-6736(20)30798-4

5. (U) A Multicenter, Adaptive, Randomized Blinded Controlled Trial of the Safety and Efficacy of Investigational Therapeutics for the Treatment of COVID-19 in Hospitalized Adults 2020. https://clinicaltrials.gov/ct2/show/NCT04280705

6. (U) Phase I, Open-Label, Dose-Ranging Study of the Safety and Immunogenicity of 2019-nCoV Vaccine (mRNA-1273) in Healthy Adults 2020.

https://clinicaltrials.gov/ct2/show/record/NCT04283461?term=mrna-1273&draw=2&rank=1

7. (U) Rapid Expert Consultation on the Possibility of Bioaerosol Spread of SARS-CoV-2 for the COVID-19 Pandemic (April 1, 2020). The National Academies Press: Washington, DC, 2020.

https://www.nap.edu/catalog/25769/rapid-expert-consultation-on-the-possibility-of-bioaerosol-spreadof-sars-cov-2-for-the-covid-19-pandemic-april-1-2020

8. (U) Severe Outcomes Among Patients with Coronavirus Disease 2019 (COVID-19) — United States, February 12–March 16, 2020. . *MMWR* **2020**.

https://www.cdc.gov/mmwr/volumes/69/wr/mm6912e2.htm?s\_cid=mm6912e2\_w#suggestedcitation 9. (U) A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia (COVACTA).

https://clinicaltrials.gov/ct2/show/NCT04320615?term=actemra&cond=covid&draw=2.

10. (U) [Wuhan Pneumonia] The Hospital Authority stated that 2 critically ill patients needed external life support treatment. <u>https://www.singtao.ca/4037242/2020-01-14/news-</u>

%E3%80%90%E6%AD%A6%E6%BC%A2%E8%82%BA%E7%82%8E%E3%80%91%E9%86%AB%E7%AE%A1 %E5%B1%80%E6%8C%872%E5%90%8D%E9%87%8D%E7%97%87%E7%97%85%E6%82%A3%E9%9C%80 %E9%AB%94%E5%A4%96%E7%94%9F%E5%91%BD%E6%94%AF%E6%8C%81%E6%B2%BB%E7%99%82/ ?variant=zh-hk.

11. (U) AAAS, You may be able to spread coronavirus just by breathing, new report finds. *Science* 2 April, 2020.

12. (U) Agency, U. S. E. P., EPA's Registered Antimicrobial Products for Use Against Novel Coronavirus SARS-CoV-2, the Cause of COVID-19. <u>https://www.epa.gov/pesticide-registration/list-n-disinfectants-use-against-sars-cov-2</u>.

13. (U) Agrawal, A. S.; Garron, T.; Tao, X.; Peng, B. H.; Wakamiya, M.; Chan, T. S.; Couch, R. B.; Tseng, C. T., Generation of a transgenic mouse model of Middle East respiratory syndrome coronavirus infection and disease. *J Virol* **2015**, *89* (7), 3659-70.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4403411/pdf/zjv3659.pdf

14. (U) Amanat, F.; Krammer, F., SARS-CoV-2 vaccines: status report. *Journal of Immunology* **2020**, *Early View*. <u>https://marlin-prod.literatumonline.com/pb-assets/journals/research/immunity/SARS-CoV-2%20vaccines%20status%20report.pdf</u>

15. (U) Andersen, K. G.; Rambaut, A.; Lipkin, W. I.; Holmes, E. C.; Garry, R. F., The proximal origin of SARS-CoV-2. *Nature Medicine* **2020**. <u>https://doi.org/10.1038/s41591-020-0820-9</u>

16. (U) Anderson, K., Estimates of the clock and TMRCA for 2019-nCoV based on 27 genomes. <u>http://virological.org/t/clock-and-tmrca-based-on-27-genomes/347</u> (accessed 01/26/2020).

17. (U) Angelopoulos, A. N.; Pathak, R.; Varma, R.; Jordan, M. I., Identifying and Correcting Bias from Time-and Severity-Dependent Reporting Rates in the Estimation of the COVID-19 Case Fatality Rate. *arXiv* **2020**. <u>https://arxiv.org/abs/2003.08592</u>

18. (U) Arentz, M.; Yim, E.; Klaff, L.; Lokhandwala, S.; Riedo, F. X.; Chong, M.; Lee, M., Characteristics and Outcomes of 21 Critically III Patients With COVID-19 in Washington State. *JAMA* **2020**. <u>https://doi.org/10.1001/jama.2020.4326</u>

19. (U) Assunção, M., Iceland's coronavirus testing suggests 50% of cases have no symptoms. *NY Daily News* 01 April, 2020.

20. (U) Bagheri, S. H. R.; Asghari, A. M.; Farhadi, M.; Shamshiri, A. R.; Kabir, A.; Kamrava, S. K.; Jalessi, M.; Mohebbi, A.; Alizadeh, R.; Honarmand, A. A.; Ghalehbaghi, B.; Salimi, A., Coincidence of COVID-19 epidemic and olfactory dysfunction outbreak. *medRxiv* **2020**, 2020.03.23.20041889. http://medrxiv.org/content/early/2020/03/27/2020.03.23.20041889.abstract

21. (U) Bai, Y.; Yao, L.; Wei, T.; Tian, F.; Jin, D.-Y.; Chen, L.; Wang, M., Presumed Asymptomatic Carrier

Transmission of COVID-19. JAMA.

22. (U) Bamford, P.; Bentley, A.; Dean, J.; Whitemore, D.; Wilson-Baig, N., *ICS Guidance for the Prone Positioning of the Conscious COVID Patient 2020*; Intensive Care Society: 2020. <u>https://emcrit.org/wp-content/uploads/2020/04/2020-04-12-Guidance-for-conscious-proning.pdf</u>

23. (U) Bao, L.; Deng, W.; Gao, H.; Xiao, C.; Liu, J.; Xue, J.; Lv, Q.; Liu, J.; Yu, P.; Xu, Y.; Qi, F.; Qu, Y.; Li, F.; Xiang, Z.; Yu, H.; Gong, S.; Liu, M.; Wang, G.; Wang, S.; Song, Z.; Zhao, W.; Han, Y.; Zhao, L.; Liu, X.; Wei, Q.; Qin, C., Reinfection could not occur in SARS-CoV-2 infected rhesus macaques. *bioRxiv* **2020**, 2020.03.13.990226.

https://www.biorxiv.org/content/biorxiv/early/2020/03/14/2020.03.13.990226.full.pdf

24. (U) Barnard, D. L.; Hubbard, V. D.; Burton, J.; Smee, D. F.; Morrey, J. D.; Otto, M. J.; Sidwell, R. W., Inhibition of severe acute respiratory syndrome-associated coronavirus (SARSCoV) by calpain inhibitors and beta-D-N4-hydroxycytidine. *Antivir Chem Chemother* **2004**, *15* (1), 15-22.

https://journals.sagepub.com/doi/pdf/10.1177/095632020401500102

25. (U) BBC, Coronavirus: California declares emergency after death. *BBC* 2020.

26. (U) Bedford, T., Cryptic Transmission of novel coronavirus revealed by genomic epidemiology. <u>https://bedford.io/blog/ncov-cryptic-transmission/</u>.

27. (U) Bedford, T.; Neher, R., Genomic epidemiology of novel coronavirus (nCoV) using data from GISAID. <u>https://nextstrain.org/ncov</u>.

28. (U) Belhadi, D.; Peiffer-Smadja, N.; Yazdanpanah, Y.; Mentré, F.; Laouénan, C., A brief review of antiviral drugs evaluated in registered clinical trials for COVID-19. *medRxiv* **2020**, 2020.03.18.20038190. <u>https://www.medrxiv.org/content/medrxiv/early/2020/03/20/2020.03.18.20038190.full.pdf</u>

29. (U) BGI, BGI Responds to Novel Coronavirus with Real-Time Detection Kits, Deploys Emergency Team to Wuhan. 2020. <u>https://www.bgi.com/global/company/news/bgi-responds-to-novel-coronavirus-with-real-time-detection-kits-deploys-emergency-team-to-wuhan/</u>

30. (U) Biotech, M., Mesa Biotech Receives Emergency Use Authorization from FDA for a 30 Minute Point of Care Molecular COVID-19 Test. Mesa Biotech: 2020.

https://www.mesabiotech.com/news/euacoronavirus

31. (U) Branswell, H., Sanofi announces it will work with HHS to develop a coronavirus vaccine. Statnews, Ed. 2020. <u>https://www.statnews.com/2020/02/18/sanofi-announces-it-will-work-with-hhs-to-develop-coronavirus-vaccine/</u>

32. (U) Brennan, Z., FDA issues 2nd EUA for decontamination system for N95 masks. *Regulatory Focus* 2020.

33. (U) Brosseau, L. M., COMMENTARY: COVID-19 transmission messages should hinge on science. <u>http://www.cidrap.umn.edu/news-perspective/2020/03/commentary-covid-19-transmission-messages-should-hinge-science</u>.

34. (U) Brosseau, L. M.; Jones, R., Commentary: Protecting health workers from airborne MERS-CoV - learning from SARS. <u>http://www.cidrap.umn.edu/news-perspective/2014/05/commentary-protecting-health-workers-airborne-mers-cov-learning-sars</u>.

35. (U) Bryner, J., First US infant death linked to COVID-19 reported in Illinois. *LiveScience* 2020.
36. (U) Callow, K.; Parry, H.; Sergeant, M.; Tyrrell, D., The time course of the immune response to experimental coronavirus infection of man. *Epidemiology & Infection* 1990, *105* (2), 435-446.

37. (U) Cao, B.; Wang, Y.; Wen, D.; Liu, W.; Wang, J.; Fan, G.; Ruan, L.; Song, B.; Cai, Y.; Wei, M.; Li, X.; Xia, J.; Chen, N.; Xiang, J.; Yu, T.; Bai, T.; Xie, X.; Zhang, L.; Li, C.; Yuan, Y.; Chen, H.; Li, H.; Huang, H.; Tu, S.; Gong, F.; Liu, Y.; Wei, Y.; Dong, C.; Zhou, F.; Gu, X.; Xu, J.; Liu, Z.; Zhang, Y.; Li, H.; Shang, L.; Wang, K.; Li, K.; Zhou, X.; Dong, X.; Qu, Z.; Lu, S.; Hu, X.; Ruan, S.; Luo, S.; Wu, J.; Peng, L.; Cheng, F.; Pan, L.; Zou, J.; Jia, C.; Wang, J.; Liu, X.; Wang, S.; Wu, X.; Ge, Q.; He, J.; Zhan, H.; Qiu, F.; Guo, L.; Huang, C.; Jaki, T.; Hayden, F. G.; Horby, P. W.; Zhang, D.; Wang, C., A Trial of Lopinavir–Ritonavir in Adults Hospitalized with Severe Covid-19. *New England Journal of Medicine* **2020**.

https://www.nejm.org/doi/full/10.1056/NEJMoa2001282

38. (U) Cao, W.; Liu, X.; Bai, T.; Fan, H.; Hong, K.; Song, H.; Han, Y.; Lin, L.; Ruan, L.; Li, T., High-dose intravenous immunoglobulin as a therapeutic option for deteriorating patients with Coronavirus Disease 2019. *Open Forum Infectious Diseases* **2020**. <u>https://doi.org/10.1093/ofid/ofaa102</u>

39. (U) Casadevall, A.; Pirofski, L.-a., The convalescent sera option for containing COVID-19. *The Journal of Clinical Investigation* **2020**, *130* (4). <u>https://doi.org/10.1172/JCI138003</u>

40. (U) Casanova, L. M.; Jeon, S.; Rutala, W. A.; Weber, D. J.; Sobsey, M. D., Effects of air temperature and relative humidity on coronavirus survival on surfaces. *Applied and environmental microbiology* **2010**, *76* (9), 2712-2717. https://www.ncbi.nlm.nih.gov/pubmed/20228108

41. (U) CDC, 2019 Novel Coronavirus RT-PCR Identification Protocols.

https://www.cdc.gov/coronavirus/2019-ncov/lab/rt-pcr-detection-instructions.html.

42. (U) CDC, Confirmed 2019-nCoV Cases Globally. <u>https://www.cdc.gov/coronavirus/2019-ncov/locations-confirmed-cases.html</u>.

43. (U) CDC, Interim Clinical Guidance for Management of Patients with Confirmed Coronavirus Disease 2019 (COVID-19). <u>https://www.cdc.gov/coronavirus/2019-ncov/hcp/clinical-guidance-management-patients.html</u>.

44. (U) CDC, Interim healthcare infection prevention and control recommendations for patients under investigation for 2019 novel coronavirus. <u>https://www.cdc.gov/coronavirus/2019-ncov/infection-control.html</u>.

45. (U) CDC, Recommendation Regarding the Use of Cloth Face Coverings, Especially in Areas of Significant Community-Based Transmission. **2020**. <u>https://www.cdc.gov/coronavirus/2019-ncov/prevent-getting-sick/cloth-face-cover.html</u>

46. (U) CDC, Situation summary. <u>https://www.cdc.gov/coronavirus/2019-nCoV/summary.html</u>.
47. (U) CDC, Symptoms. <u>https://www.cdc.gov/coronavirus/2019-ncov/about/symptoms.html</u>.

48. (U) CDC, C., China's CDC detects a large number of new coronaviruses in the South China seafood market in Wuhan <u>http://www.chinacdc.cn/yw\_9324/202001/t20200127\_211469.html</u> (accessed 01/27/2020).

49. (U) CenterWatch, SAB Biotherapeutics wins BARDA MERS treatment contract. <u>https://www.centerwatch.com/articles/14742</u>.

50. (U) Chan, J. F.-W.; Yuan, S.; Kok, K.-H.; To, K. K.-W.; Chu, H.; Yang, J.; Xing, F.; Liu, J.; Yip, C. C.-Y.; Poon, R. W.-S.; Tsoi, H.-W.; Lo, S. K.-F.; Chan, K.-H.; Poon, V. K.-M.; Chan, W.-M.; Ip, J. D.; Cai, J.-P.; Cheng, V. C.-C.; Chen, H.; Hui, C. K.-M.; Yuen, K.-Y., A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster. *The Lancet* **2020**. <u>https://www.sciencedirect.com/science/article/pii/S0140673620301549</u>

51. (U) Chan, J. F.; Zhang, A. J.; Yuan, S.; Poon, V. K.; Chan, C. C.; Lee, A. C.; Chan, W. M.; Fan, Z.; Tsoi, H. W.; Wen, L.; Liang, R.; Cao, J.; Chen, Y.; Tang, K.; Luo, C.; Cai, J. P.; Kok, K. H.; Chu, H.; Chan, K. H.; Sridhar, S.; Chen, Z.; Chen, H.; To, K. K.; Yuen, K. Y., Simulation of the clinical and pathological manifestations of Coronavirus Disease 2019 (COVID-19) in golden Syrian hamster model: implications for disease pathogenesis and transmissibility. *Clin Infect Dis* **2020**.

https://www.ncbi.nlm.nih.gov/pubmed/32215622

52. (U) Chan, K. H.; Peiris, J. S.; Lam, S. Y.; Poon, L. L.; Yuen, K. Y.; Seto, W. H., The Effects of Temperature and Relative Humidity on the Viability of the SARS Coronavirus. *Adv Virol* **2011**, *2011*, 734690. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3265313/pdf/AV2011-734690.pdf

53. (U) Chang, D.; Lin, M.; Wei, L.; Xie, L.; Zhu, G.; Dela Cruz, C. S.; Sharma, L., Epidemiologic and Clinical Characteristics of Novel Coronavirus Infections Involving 13 Patients Outside Wuhan, China. *JAMA* **2020**. <u>https://doi.org/10.1001/jama.2020.1623</u>

https://jamanetwork.com/journals/jama/articlepdf/2761043/jama\_chang\_2020\_ld\_200007.pdf 54. (U) Changzheng, L. J. L., Experts in the medical treatment team: Wuhan's unexplained viral pneumonia patients can be controlled more. <u>https://www.cn-healthcare.com/article/20200110/content-528579.html</u>.

55. (U) Chen, C.; Cao, M.; Peng, L.; Guo, X.; Yang, F.; Wu, W.; Chen, L.; Yang, Y.; Liu, Y.; Wang, F., Coronavirus Disease-19 Among Children Outside Wuhan, China. *SSRN* **2020**. <u>https://papers.ssrn.com/sol3/papers.cfm?abstract\_id=3546071</u>

56. (U) Chen, C.; Huang, J.; Cheng, Z.; Wu, J.; Chen, S.; Zhang, Y.; Chen, B.; Lu, M.; Luo, Y.; Zhang, J.; Yin, P.; Wang, X., Favipiravir versus Arbidol for COVID-19: A Randomized Clinical Trial. *medRxiv* **2020**, 2020.03.17.20037432.

https://www.medrxiv.org/content/medrxiv/early/2020/03/20/2020.03.17.20037432.full.pdf

57. (U) Chen, H.; Guo, J.; Wang, C.; Luo, F.; Yu, X.; Zhang, W.; Li, J.; Zhao, D.; Xu, D.; Gong, Q., Clinical characteristics and intrauterine vertical transmission potential of COVID-19 infection in nine pregnant women: a retrospective review of medical records. *The Lancet* **2020**, *395* (10226), 809-815.

58. (U) Chen, N.; Zhou, M.; Dong, X.; Qu, J.; Gong, F.; Han, Y.; Qiu, Y.; Wang, J.; Liu, Y.; Wei, Y.; Xia, J.; Yu, T.; Zhang, X.; Zhang, L., Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. *Lancet* **2020**.

https://www.ncbi.nlm.nih.gov/pubmed/32007143

59. (U) Chen, Y.; Peng, H.; Wang, L.; Zhao, Y.; Zeng, L.; Gao, H.; Liu, Y., Infants Born to Mothers With a New Coronavirus (COVID-19). *Frontiers in Pediatrics* **2020**, *8* (104).

https://www.frontiersin.org/article/10.3389/fped.2020.00104

60. (U) Chin, A.; Chu, J.; Perera, M.; Hui, K.; Yen, H.-L.; Chan, M.; Peiris, M.; Poon, L., Stability of SARS-CoV-2 in different environmental conditions. *medRxiv* **2020**, 2020.03.15.20036673.

https://www.medrxiv.org/content/medrxiv/early/2020/03/27/2020.03.15.20036673.full.pdf

61. (U) Chin, A. W. H.; Chu, J. T. S.; Perera, M. R. A.; Hui, K. P. Y.; Yen, H.-L.; Chan, M. C. W.; Peiris, M.; Poon, L. L. M., Stability of SARS-CoV-2 in different environmental conditions. *The Lancet Microbe*. https://doi.org/10.1016/S2666-5247(20)30003-3

62. (U) Chughtai, A. A.; Seale, H.; MacIntyre, C. R., Use of cloth masks in the practice of infection control—evidence and policy gaps. *Int J Infect Control* **2013**, *9* (3), doi: 10.3396/IJIC.v9i3.020.13.
63. (U) Ćirić, J., Is Iceland's coronavirus testing showing that 50% of cases have no symptoms? *Iceland Review* 02 April, 2020.

64. (U) Clifford, T., Eli Lilly CEO aims to start testing coronavirus cure 'this summer'. *CNBC* 13 March, 2020.

65. (U) Coalition, C.-C. R., Global coalition to accelerate COVID-19 clinical research in resource-limited settings. *The Lancet* 2020. <u>http://www.sciencedirect.com/science/article/pii/S0140673620307984</u>
66. (U) Cockrell, A. S.; Yount, B. L.; Scobey, T.; Jensen, K.; Douglas, M.; Beall, A.; Tang, X.-C.; Marasco, W. A.; Heise, M. T.; Baric, R. S., A mouse model for MERS coronavirus-induced acute respiratory distress syndrome. *Nature microbiology* 2016, *2* (2), 1-11.

67. (U) Cohen, J., Mining coronavirus genomes for clues to the outbreak's origins. *Science* 2020. 68. (U) Cohen, J., Vaccine designers take first shots at COVID-19. *AAAS* **2020**, *368* (6486), 14-16. https://science.sciencemag.org/content/368/6486/14

69. (U) Cohen, J., Wuhan seafood market may not be source of novel virus spreading globally. <u>https://www.sciencemag.org/news/2020/01/wuhan-seafood-market-may-not-be-source-novel-virus-spreading-globally</u> (accessed 01/27/2020).

70. (U) Control), E. E. C. f. D. P. a., *Interim guidance for environmental cleaning in non-healthcare facilities exposed to SARS-CoV-2*; European Centre for Disease Prevention and Control: European Centre for Disease Prevention and Control, 2020. <u>https://www.ecdc.europa.eu/en/publications-data/interim-guidance-environmental-cleaning-non-healthcare-facilities-exposed-2019#no-link</u>

71. (U) Corman, V. M.; Landt, O.; Kaiser, M.; Molenkamp, R.; Meijer, A.; Chu, D. K.; Bleicker, T.; Brunink, S.; Schneider, J.; Schmidt, M. L.; Mulders, D. G.; Haagmans, B. L.; van der Veer, B.; van den Brink, S.; Wijsman, L.; Goderski, G.; Romette, J. L.; Ellis, J.; Zambon, M.; Peiris, M.; Goossens, H.; Reusken, C.; Koopmans, M. P.; Drosten, C., Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR. *Euro Surveill* **2020**, *25* (3). <u>https://www.ncbi.nlm.nih.gov/pubmed/31992387</u>

72. (U) Coughlin, M. M.; Prabhakar, B. S., Neutralizing human monoclonal antibodies to severe acute respiratory syndrome coronavirus: target, mechanism of action, and therapeutic potential. *Reviews in medical virology* **2012**, *22* (1), 2-17. <u>https://www.ncbi.nlm.nih.gov/pubmed/21905149</u>

73. (U) Cowling, B. J.; Ali, S. T.; Ng, T. W. Y.; Tsang, T. K.; Li, J. C. M.; Fong, M. W.; Liao, Q.; Kwan, M. Y.; Lee, S. L.; Chiu, S. S.; Wu, J. T.; Wu, P.; Leung, G. M., Impact assessment of non-pharmaceutical interventions against COVID-19 and influenza in Hong Kong: an observational study. *medRxiv* **2020**, 2020.03.12.20034660.

https://www.medrxiv.org/content/medrxiv/early/2020/03/16/2020.03.12.20034660.full.pdf

74. (U) Daily, H., Wuhan Institute of Virology, Chinese Academy of Sciences and others have found that 3 drugs have a good inhibitory effect on new coronavirus. Chen, L., Ed. 2020.

http://news.cnhubei.com/content/2020-01/28/content\_12656365.html

75. (U) Dandekar, R.; Barbastathis, G., Neural Network aided quarantine control model estimation of global Covid-19 spread. *arXiv preprint arXiv:2004.02752* **2020**.

76. (U) Dato, V. M.; Hostler, D.; Hahn, M. E., Simple respiratory mask. *Emerg Infect Dis* **2006**, *12* (6), 1033-4. <u>https://www.ncbi.nlm.nih.gov/pubmed/16752475</u>

77. (U) Davies, A.; Thompson, K. A.; Giri, K.; Kafatos, G.; Walker, J.; Bennett, A., Testing the efficacy of homemade masks: would they protect in an influenza pandemic? *Disaster Med Public Health Prep* **2013**, 7 (4), 413-8. <u>https://www.ncbi.nlm.nih.gov/pubmed/24229526</u>

78. (U) De Albuquerque, N.; Baig, E.; Ma, X.; Zhang, J.; He, W.; Rowe, A.; Habal, M.; Liu, M.; Shalev, I.; Downey, G. P.; Gorczynski, R.; Butany, J.; Leibowitz, J.; Weiss, S. R.; McGilvray, I. D.; Phillips, M. J.; Fish, E. N.; Levy, G. A., Murine hepatitis virus strain 1 produces a clinically relevant model of severe acute respiratory syndrome in A/J mice. *J Virol* **2006**, *80* (21), 10382-94.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1641767/pdf/0747-06.pdf

79. (U) de Haan, C. A. M.; Haijema, B. J.; Schellen, P.; Schreur, P. W.; te Lintelo, E.; Vennema, H.; Rottier, P. J. M., Cleavage of Group 1 Coronavirus Spike Proteins: How Furin Cleavage Is Traded Off against Heparan Sulfate Binding upon Cell Culture Adaptation. *Journal of Virology* **2008**, *82* (12), 6078-6083. https://jvi.asm.org/content/jvi/82/12/6078.full.pdf 80. (U) Dediego, M. L.; Pewe, L.; Alvarez, E.; Rejas, M. T.; Perlman, S.; Enjuanes, L., Pathogenicity of severe acute respiratory coronavirus deletion mutants in hACE-2 transgenic mice. *Virology* **2008**, *376* (2), 379-389. <u>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2810402/</u>

81. (U) Deng, W.; Bao, L.; Gao, H.; Xiang, Z.; Qu, Y.; Song, Z.; Gong, S.; Liu, J.; Liu, J.; Yu, P.; Qi, F.; Xu, Y.; Li, F.; Xiao, C.; Lv, Q.; Xue, J.; Wei, Q.; Liu, M.; Wang, G.; Wang, S.; Yu, H.; Liu, X.; Zhao, W.; Han, Y.; Qin, C., Ocular conjunctival inoculation of SARS-CoV-2 can cause mild COVID-19 in Rhesus macaques. *bioRxiv* **2020**.

82. (U) Deng, W.; Bao, L.; Gao, H.; Xiang, Z.; Qu, Y.; Song, Z.; Gong, S.; Liu, J.; Liu, J.; Yu, P.; Qi, F.; Xu, Y.; Li, F.; Xiao, C.; Lv, Q.; Xue, J.; Wei, Q.; Liu, M.; Wang, G.; Wang, S.; Yu, H.; Liu, X.; Zhao, W.; Han, Y.; Qin, C., Rhesus macaques can be effectively infected with SARS-CoV-2 via ocular conjunctival route. *bioRxiv* **2020**, 2020.03.13.990036.

https://www.biorxiv.org/content/biorxiv/early/2020/03/14/2020.03.13.990036.full.pdf

83. (U) Dong, N.; Yang, X.; Ye, L.; Chen, K.; Chan, E. W.-C.; Yang, M.; Chen, S., Genomic and protein structure modelling analysis depicts the origin and infectivity of 2019-nCoV, a new coronavirus which caused a pneumonia outbreak in Wuhan, China. *bioRxiv* **2020**, 2020.01.20.913368.

https://www.biorxiv.org/content/biorxiv/early/2020/01/22/2020.01.20.913368.full.pdf

84. (U) Dong, Y.; Mo, X.; Hu, Y.; Qi, X.; Jiang, F.; Jiang, Z.; Tong, S., Epidemiological Characteristics of 2143 Pediatric Patients With 2019 Coronavirus Disease in China. *Pediatrics* **2020**, e20200702.

https://pediatrics.aappublications.org/content/pediatrics/early/2020/03/16/peds.2020-0702.full.pdf

85. (U) Du, Z.; Xu, X.; Wu, Y.; Wang, L.; Cowling, B. J.; Meyers, L. A., The serial interval of COVID-19 from publicly reported confirmed cases. *medRxiv* **2020**, 2020.02.19.20025452.

https://www.medrxiv.org/content/medrxiv/early/2020/03/13/2020.02.19.20025452.full.pdf

86. (U) Duan, S.; Zhao, X.; Wen, R.; Huang, J.-j.; Pi, G.; Zhang, S.; Han, J.; Bi, S.; Ruan, L.; Dong, X.-p., Stability of SARS coronavirus in human specimens and environment and its sensitivity to heating and UV irradiation. *Biomedical and environmental sciences: BES* **2003**, *16* (3), 246-255.

87. (U) Duan, S. M.; Zhao, X. S.; Wen, R. F.; Huang, J. J.; Pi, G. H.; Zhang, S. X.; Han, J.; Bi, S. L.; Ruan, L.; Dong, X. P., Stability of SARS coronavirus in human specimens and environment and its sensitivity to heating and UV irradiation. *Biomed Environ Sci* **2003**, *16* (3), 246-55.

88. (U) EuroTimes, Pfizer/BioNTech target April vaccine trial launch. EuroTimes 2020.

89. (U) Falconer, E., To Develop Coronavirus Treatment, Lilly Taps AbCellera Antibody Platform. In *Genetic Engineering & Biotechnology News*, 2020. <u>https://www.genengnews.com/news/to-develop-</u>coronavirus-treatment-lilly-taps-abcellera-antibody-platform/

90. (U) FDA, *Emergency Use Authorization*; Food and Drug Administration: 2020.

https://www.fda.gov/media/136529/download

91. (U) FDA, ID NOW COVID-19; Food and Drug Administration: 2020.

https://www.fda.gov/media/136525/download

92. (U) FDA, *Investigational COVID-19 Convalescent Plasma - Emergency INDs*; Food and Drug Administration: 2020. <u>https://www.fda.gov/vaccines-blood-biologics/investigational-new-drug-ind-or-</u>device-exemption-ide-process-cber/investigational-covid-19-convalescent-plasma-emergency-inds

93. (U) FDA, Policy for Diagnostics Testing in Laboratories Certified to Perform High Complexity Testing under CLIA prior to Emergency Use Authorization for Coronavirus Disease-2019 during the Public Health Emergency; Immediately in Effect Guidance for Industry and Food and Drug Administration Staff. 2020. https://www.regulations.gov/docket?D=FDA-2020-D-0987

94. (U) Ferguson, N.; Laydon, D.; Nedjati-Gilani, G.; Imai, N.; Ainslie, K.; Baguelin, M.; Bhatia, S.; Boonyasiri, A.; Cucunuba, Z.; Cuomo-Dannenburg, G.; Dighe, A.; Dorigatti, I.; Fu, H.; Gaythorpe, K.; Green, W.; Hamlet, A.; Hinsley, W.; Okell, L.; van Elsland, S.; Thompson, H.; Verity, R.; Volz, E.; Wang, H.; Wang, Y.; Walker, P.; Walters, C.; Winskill, P.; Whittaker, C.; Donnelly, C.; Riley, S.; Ghani, A., *Impact of non-pharmaceutical interventions (NPIs) to reduce COVID-19 mortality and healthcare demand*; 2020. https://www.imperial.ac.uk/media/imperial-college/medicine/sph/ide/gida-fellowships/Imperial-College-COVID19-NPI-modelling-16-03-2020.pdf

95. (U) Garg, S., Hospitalization Rates and Characteristics of Patients Hospitalized with Laboratory-Confirmed Coronavirus Disease 2019—COVID-NET, 14 States, March 1–30, 2020. *MMWR. Morbidity and Mortality Weekly Report* **2020**, *69*.

96. (U) Gautier, J.-F.; Ravussin, Y., A New Symptom of COVID-19: Loss of Taste and Smell. *Obesity* **2020**, *n/a* (n/a). <u>https://doi.org/10.1002/oby.22809</u>

97. (U) Gautret, P.; Lagier, J.-C.; Parola, P.; Meddeb, L.; Mailhe, M.; Doudier, B.; Courjon, J.; Giordanengo, V.; Vieira, V. E.; Dupont, H. T., Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. *International Journal of Antimicrobial Agents* **2020**, 105949.

98. (U) GitHub Inc., Reproducible analyses for rejecting rare genomic inversions in SARS-CoV-2. https://github.com/alexcritschristoph/sars\_cov\_2\_inversion (accessed 04 April).

99. (U) Guan, L.; Zhou, L.; Zhang, J.; Peng, W.; Chen, R., More awareness is needed for severe acute respiratory syndrome coronavirus 2019 transmission through exhaled air during non-invasive respiratory support: experience from China. *European Respiratory Journal* **2020**, *55* (3), 2000352. https://erj.ersjournals.com/content/erj/55/3/2000352.full.pdf

100. (U) Guan, W.-j.; Ni, Z.-y.; Hu, Y.; Liang, W.-h.; Ou, C.-q.; He, J.-x.; Liu, L.; Shan, H.; Lei, C.-l.; Hui, D. S.; Du, B.; Li, L.-j.; Zeng, G.; Yuen, K.-Y.; Chen, R.-c.; Tang, C.-l.; Wang, T.; Chen, P.-y.; Xiang, J.; Li, S.-y.; Wang, J.-l.; Liang, Z.-j.; Peng, Y.-x.; Wei, L.; Liu, Y.; Hu, Y.-h.; Peng, P.; Wang, J.-m.; Liu, J.-y.; Chen, Z.; Li, G.; Zheng, Z.-j.; Qiu, S.-q.; Luo, J.; Ye, C.-j.; Zhu, S.-y.; Zhong, N.-s., Clinical characteristics of 2019 novel coronavirus infection in China. *medRxiv* **2020**, 2020.02.06.20020974.

https://www.medrxiv.org/content/medrxiv/early/2020/02/09/2020.02.06.20020974.full.pdf

101. (U) Guérin, C.; Reignier, J.; Richard, J.-C.; Beuret, P.; Gacouin, A.; Boulain, T.; Mercier, E.; Badet, M.; Mercat, A.; Baudin, O.; Clavel, M.; Chatellier, D.; Jaber, S.; Rosselli, S.; Mancebo, J.; Sirodot, M.; Hilbert, G.; Bengler, C.; Richecoeur, J.; Gainnier, M.; Bayle, F.; Bourdin, G.; Leray, V.; Girard, R.; Baboi, L.; Ayzac, L., Prone Positioning in Severe Acute Respiratory Distress Syndrome. *New England Journal of Medicine* **2013**, *368* (23), 2159-2168. <u>https://www.nejm.org/doi/full/10.1056/NEJMoa1214103</u>

102. (U) Herold, T.; Jurinovic, V.; Arnreich, C.; Hellmuth, J. C.; Bergwelt-Baildon, M.; Klein, M.; Weinberger, T., Level of IL-6 predicts respiratory failure in hospitalized symptomatic COVID-19 patients. *medRxiv* **2020**, 2020.04.01.20047381.

https://www.medrxiv.org/content/medrxiv/early/2020/04/04/2020.04.01.20047381.full.pdf 103. (U) HHS, 2019-nCoV Update. 2020. https://www.hhs.gov/live/live-

2/index.html?CDC\_AA\_refVal=https%3A%2F%2Fwww.cdc.gov%2Fmedia%2Freleases%2F2020%2Fa0128 -hhs-coronavirus-update.html#11465

104. (U) Hill, V.; Rambaut, A., Phylodynamic analysis of SARS-CoV-2 | Update 2020-03-06. Virological: 2020. <u>http://virological.org/t/phylodynamic-analysis-of-sars-cov-2-update-2020-03-06/420</u>

105. (U) Hinton, D., qSARS-CoV-2 IgG/IgM Rapid Test- Letter of Authorization. FDA, Ed. FDA: 2020. https://www.fda.gov/media/136622/download

106. (U) Hoehl, S.; Berger, A.; Kortenbusch, M.; Cinatl, J.; Bojkova, D.; Rabenau, H.; Behrens, P.; Böddinghaus, B.; Götsch, U.; Naujoks, F.; Neumann, P.; Schork, J.; Tiarks-Jungk, P.; Walczok, A.; Eickmann, M.; Vehreschild, M. J. G. T.; Kann, G.; Wolf, T.; Gottschalk, R.; Ciesek, S., Evidence of SARS-CoV-2 Infection in Returning Travelers from Wuhan, China. *New England Journal of Medicine* **2020**. https://www.nejm.org/doi/full/10.1056/NEJMc2001899

107. (U) Huang, C.; Wang, Y.; Li, X.; Ren, L.; Zhao, J.; Hu, Y.; Zhang, L.; Fan, G.; Xu, J.; Gu, X.; Cheng, Z.; Yu, T.; Xia, J.; Wei, Y.; Wu, W.; Xie, X.; Yin, W.; Li, H.; Liu, M.; Xiao, Y.; Gao, H.; Guo, L.; Xie, J.; Wang, G.; Jiang, R.; Gao, Z.; Jin, Q.; Wang, J.; Cao, B., Clinical features of patients infected with 2019 novel coronavirus in

Wuhan, China. *The Lancet* **2020**. <u>https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)30183-5/fulltext</u>

108. (U) Hulkower, R. L.; Casanova, L. M.; Rutala, W. A.; Weber, D. J.; Sobsey, M. D., Inactivation of surrogate coronaviruses on hard surfaces by health care germicides. *American journal of infection control* **2011**, *39* (5), 401-407. <u>https://www.sciencedirect.com/science/article/pii/S0196655310009004</u> 109. (U) IDEXX, Leading Veterinary Diagnostic Company Sees No COVID-19 Cases in Pets. IDEXX: 2020. https://www.idexx.com/en/about-idexx/news/no-covid-19-cases-pets/

110. (U) Imai, N.; Dorigatti, I.; Cori, A.; Riley, S.; Ferguson, N., Estimating the potential total number of novel Coronavirus cases in Wuhan City, China. <u>https://www.imperial.ac.uk/media/imperial-</u>college/medicine/sph/ide/gida-fellowships/2019-nCoV-outbreak-report-17-01-2020.pdf

111. (U) Iwata, K.; Doi, A.; Miyakoshi, C., Was School Closure Effective in Mitigating Coronavirus Disease 2019 (COVID-19)? Time Series Analysis Using Bayesian Inference. **2020**.

112. (U) JHU, Coronavirus COVID-19 Global Cases by Johns Hopkins CSSE.

https://gisanddata.maps.arcgis.com/apps/opsdashboard/index.html#/bda7594740fd40299423467b48e 9ecf6.

114. (U) Johndrow, J. E.; Lum, K.; Ball, P., Estimating SARS-CoV-2-positive Americans using deaths-only data. *arXiv preprint arXiv:2004.02605* **2020**.

115. (U) Johnson, J. a., Johnson & Johnson Announces a Lead Vaccine Candidate for COVID-19; Landmark New Partnership with U.S. Department of Health & Human Services; and Commitment to Supply One Billion Vaccines Worldwide for Emergency Pandemic Use. Johnson and Johnson: 2020.

https://www.jnj.com/johnson-johnson-announces-a-lead-vaccine-candidate-for-covid-19-landmarknew-partnership-with-u-s-department-of-health-human-services-and-commitment-to-supply-onebillion-vaccines-worldwide-for-emergency-pandemic-use

116. (U) Joseph, A., CDC developing serologic tests that could reveal full scope of U.S. coronavirus outbreak. *STAT* 2020.

117. (U) Karamitros, T.; Papadopoulou, G.; Bousali, M.; Mexias, A.; Tsiodras, S.; Mentis, A., SARS-CoV-2 exhibits intra-host genomic plasticity and low-frequency polymorphic quasispecies. *bioRxiv* **2020**, 2020.03.27.009480. <u>http://biorxiv.org/content/early/2020/03/28/2020.03.27.009480.abstract</u>

118. (U) Kim, Y.-I.; Kim, S.-G.; Kim, S.-M.; Kim, E.-H.; Park, S.-J.; Yu, K.-M.; Chang, J.-H.; Kim, E. J.; Lee, S.; Casel, M. A. B.; Um, J.; Song, M.-S.; Jeong, H. W.; Lai, V. D.; Kim, Y.; Chin, B. S.; Park, J.-S.; Chung, K.-H.; Foo, S.-S.; Poo, H.; Mo, I.-P.; Lee, O.-J.; Webby, R. J.; Jung, J. U.; Choi, Y. K., Infection and Rapid Transmission of SARS-CoV-2 in Ferrets. *Cell Host & Microbe* **2020**.

http://www.sciencedirect.com/science/article/pii/S1931312820301876

119. (U) Kraemer, M. U. G.; Yang, C.-H.; Gutierrez, B.; Wu, C.-H.; Klein, B.; Pigott, D. M.; du Plessis, L.; Faria, N. R.; Li, R.; Hanage, W. P.; Brownstein, J. S.; Layan, M.; Vespignani, A.; Tian, H.; Dye, C.; Pybus, O. G.; Scarpino, S. V., The effect of human mobility and control measures on the COVID-19 epidemic in China. *Science* **2020**, eabb4218.

https://science.sciencemag.org/content/sci/early/2020/03/25/science.abb4218.full.pdf

120. (U) Kratzel, A.; Todt, D.; V'kovski, P.; Steiner, S.; Gultom, M. L.; Thao, T. T. N.; Ebert, N.; Holwerda, M.; Steinmann, J.; Niemeyer, D.; Dijkman, R.; Kampf, G.; Drosten, C.; Steinmann, E.; Thiel, V.; Pfaender, S., Efficient inactivation of SARS-CoV-2 by WHO-recommended hand rub formulations and alcohols. *bioRxiv* **2020**, 2020.03.10.986711.

https://www.biorxiv.org/content/biorxiv/early/2020/03/17/2020.03.10.986711.full.pdf

121. (U) Kupferschmidt, K.; Cohen, J., WHO launches global megatrial of the four most promising coronavirus treatments. *Science* 2020.

122. (U) Lai, M. Y.; Cheng, P. K.; Lim, W. W., Survival of severe acute respiratory syndrome coronavirus. *Clinical Infectious Diseases* **2005**, *41* (7), e67-e71.

https://academic.oup.com/cid/article/41/7/e67/310340

123. (U) Lam, T. T.-Y.; Shum, M. H.-H.; Zhu, H.-C.; Tong, Y.-G.; Ni, X.-B.; Liao, Y.-S.; Wei, W.; Cheung, W. Y.-M.; Li, W.-J.; Li, L.-F.; Leung, G. M.; Holmes, E. C.; Hu, Y.-L.; Guan, Y., Identifying SARS-CoV-2 related coronaviruses in Malayan pangolins. *Nature* **2020**. <u>https://doi.org/10.1038/s41586-020-2169-0</u>

124. (U) Lan, L.; Xu, D.; Ye, G.; Xia, C.; Wang, S.; Li, Y.; Xu, H., Positive RT-PCR Test Results in Patients Recovered From COVID-19. *Jama* **2020**. <u>https://jamanetwork.com/journals/jama/fullarticle/2762452</u> 125. (U) Lau, S., Coronavirus: WHO official says there's no evidence of 'reinfected' patients in China <u>https://www.scmp.com/news/china/society/article/3074045/coronavirus-who-official-says-theres-no-</u> evidence-reinfected.

126. (U) Lauer, S. A.; Grantz, K. H.; Bi, Q.; Jones, F. K.; Zheng, Q.; Meredith, H. R.; Azman, A. S.; Reich, N. G.; Lessler, J., The Incubation Period of Coronavirus Disease 2019 (COVID-19) From Publicly Reported Confirmed Cases: Estimation and Application. *Annals of Internal Medicine* **2020**. https://doi.org/10.7326/M20-0504

127. (U) Leung, K.; Wu, J. T.; Liu, D.; Leung, G. M., First-wave COVID-19 transmissibility and severity in China outside Hubei after control measures, and second-wave scenario planning: a modelling impact assessment. *The Lancet*. <u>https://doi.org/10.1016/S0140-6736(20)30746-7</u>

128. (U) Leung, N. H. L.; Chu, D. K. W.; Shiu, E. Y. C.; Chan, K.-H.; McDevitt, J. J.; Hau, B. J. P.; Yen, H.-L.; Li, Y.; Ip, D. K. M.; Peiris, J. S. M.; Seto, W.-H.; Leung, G. M.; Milton, D. K.; Cowling, B. J., Respiratory virus shedding in exhaled breath and efficacy of face masks. *Nature Medicine* **2020**. https://doi.org/10.1038/s41591-020-0843-2

129. (U) Levine, J., Scientists race to develop vaccine to deadly China coronavirus.
<u>https://nypost.com/2020/01/25/scientists-race-to-develop-vaccine-to-deadly-china-coronavirus/</u>.
130. (U) Lewis, D., Is the coronavirus airborne? Experts can't agree. *Nature* 2020. 10.1038/d41586-020-

00974-w

131. (U) Li, K.; Wohlford-Lenane, C.; Perlman, S.; Zhao, J.; Jewell, A. K.; Reznikov, L. R.; Gibson-Corley, K. N.; Meyerholz, D. K.; McCray, P. B., Jr., Middle East Respiratory Syndrome Coronavirus Causes Multiple Organ Damage and Lethal Disease in Mice Transgenic for Human Dipeptidyl Peptidase 4. *J Infect Dis* **2016**, *213* (5), 712-22. <u>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4747621/pdf/jiv499.pdf</u>

132. (U) Li, Q.; Guan, X.; Wu, P.; Wang, X.; Zhou, L.; Tong, Y.; Ren, R.; Leung, K. S. M.; Lau, E. H. Y.; Wong, J. Y.; Xing, X.; Xiang, N.; Wu, Y.; Li, C.; Chen, Q.; Li, D.; Liu, T.; Zhao, J.; Liu, M.; Tu, W.; Chen, C.; Jin, L.; Yang, R.; Wang, Q.; Zhou, S.; Wang, R.; Liu, H.; Luo, Y.; Liu, Y.; Shao, G.; Li, H.; Tao, Z.; Yang, Y.; Deng, Z.; Liu, B.; Ma, Z.; Zhang, Y.; Shi, G.; Lam, T. T. Y.; Wu, J. T.; Gao, G. F.; Cowling, B. J.; Yang, B.; Leung, G. M.; Feng, Z., Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus–Infected Pneumonia. *New England Journal of Medicine* **2020**. <u>https://www.nejm.org/doi/full/10.1056/NEJMoa2001316</u> https://www.nejm.org/doi/10.1056/NEJMoa2001316

133. (U) Li, R.; Pei, S.; Chen, B.; Song, Y.; Zhang, T.; Yang, W.; Shaman, J., Substantial undocumented infection facilitates the rapid dissemination of novel coronavirus (SARS-CoV2). *Science* **2020**, eabb3221. <u>https://science.sciencemag.org/content/sci/early/2020/03/13/science.abb3221.full.pdf</u>

134. (U) Li, X.; Zai, J.; Zhao, Q.; Nie, Q.; Li, Y.; Foley, B. T.; Chaillon, A., Evolutionary history, potential intermediate animal host, and cross-species analyses of SARS-CoV-2. *Journal of Medical Virology* **2020**, *n/a* (n/a). <u>https://onlinelibrary.wiley.com/doi/abs/10.1002/jmv.25731</u>

135. (U) Ling, Y.; Xu, S. B.; Lin, Y. X.; Tian, D.; Zhu, Z. Q.; Dai, F. H.; Wu, F.; Song, Z. G.; Huang, W.; Chen, J.; Hu, B. J.; Wang, S.; Mao, E. Q.; Zhu, L.; Zhang, W. H.; Lu, H. Z., Persistence and clearance of viral RNA in 2019 novel coronavirus disease rehabilitation patients. *Chin Med J (Engl)* **2020**.

136. (U) Liu, H.; Wang, L.-L.; Zhao, S.-J.; Kwak-Kim, J.; Mor, G.; Liao, A.-H., Why are pregnant women susceptible to viral infection: an immunological viewpoint? *Journal of Reproductive Immunology* **2020**, 103122. <u>http://www.sciencedirect.com/science/article/pii/S0165037820300437</u>

137. (U) Liu, P.; Chen, W.; Chen, J.-P., Viral Metagenomics Revealed Sendai Virus and Coronavirus Infection of Malayan Pangolins (Manis javanica). *Viruses* **2019**, *11* (11), 979. https://www.mdpi.com/1999-4915/11/11/979

138. (U) Liu, P.; Jiang, J.-Z.; Wan, X.-F.; Hua, Y.; Wang, X.; Hou, F.; Chen, J.; Zou, J.; Chen, J., Are pangolins the intermediate host of the 2019 novel coronavirus (2019-nCoV) ? *bioRxiv* **2020**, 2020.02.18.954628. http://biorxiv.org/content/early/2020/02/20/2020.02.18.954628.abstract

139. (U) Liu, W.; Zhang, Q.; Chen, J.; Xiang, R.; Song, H.; Shu, S.; Chen, L.; Liang, L.; Zhou, J.; You, L.; Wu, P.; Zhang, B.; Lu, Y.; Xia, L.; Huang, L.; Yang, Y.; Liu, F.; Semple, M. G.; Cowling, B. J.; Lan, K.; Sun, Z.; Yu, H.; Liu, Y., Detection of Covid-19 in Children in Early January 2020 in Wuhan, China. *New England Journal of Medicine* **2020**. https://www.nejm.org/doi/full/10.1056/NEJMc2003717

140. (U) Liu, Y.; Funk, S.; Flasche, S., *The Contribution of Pre-symptomatic Transmission to the COVID-19 Outbreak*; London School of Hygiene and Tropical Medicine: 2020.

https://cmmid.github.io/topics/covid19/control-measures/pre-symptomatic-transmission.html

141. (U) Liu, Y.; Ning, Z.; Chen, Y.; Guo, M.; Liu, Y.; Gali, N. K.; Sun, L.; Duan, Y.; Cai, J.; Westerdahl, D.; Liu, X.; Ho, K.-f.; Kan, H.; Fu, Q.; Lan, K., Aerodynamic Characteristics and RNA Concentration of SARS-CoV-2 Aerosol in Wuhan Hospitals during COVID-19 Outbreak. *bioRxiv* **2020**, 2020.03.08.982637. <u>https://www.biorxiv.org/content/biorxiv/early/2020/03/10/2020.03.08.982637.full.pdf</u>

142. (U) Lowe, D., Hydroxychloroquine Update For April 6. (accessed April 7).

143. (U) Lu, J.; Plessis, L. d.; Liu, Z.; Hill, V.; Kang, M.; Lin, H.; Sun, J.; Francois, S.; Kraemer, M. U. G.; Faria, N. R.; McCrone, J. T.; Peng, J.; Xiong, Q.; Yuan, R.; Zeng, L.; Zhou, P.; Liang, C.; Yi, L.; Liu, J.; Xiao, J.; Hu, J.; Liu, T.; Ma, W.; Li, W.; Su, J.; Zheng, H.; Peng, B.; Fang, S.; Su, W.; Li, K.; Sun, R.; Bai, R.; Tang, X.; Liang, M.; Quick, J.; Song, T.; Rambaut, A.; Loman, N.; Raghwani, J.; Pybus, O.; Ke, C., Genomic epidemiology of SARS-CoV-2 in Guangdong Province, China. *medRxiv* **2020**, 2020.04.01.20047076.

https://www.medrxiv.org/content/medrxiv/early/2020/04/04/2020.04.01.20047076.full.pdf

144. (U) Lu, R.; Zhao, X.; Li, J.; Niu, P.; Yang, B.; Wu, H.; Wang, W.; Song, H.; Huang, B.; Zhu, N.; Bi, Y.; Ma, X.; Zhan, F.; Wang, L.; Hu, T.; Zhou, H.; Hu, Z.; Zhou, W.; Zhao, L.; Chen, J.; Meng, Y.; Wang, J.; Lin, Y.; Yuan, J.; Xie, Z.; Ma, J.; Liu, W. J.; Wang, D.; Xu, W.; Holmes, E. C.; Gao, G. F.; Wu, G.; Chen, W.; Shi, W.; Tan, W., Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. *The Lancet* **2020**. https://doi.org/10.1016/S0140-6736(20)30251-8

145. (U) Lu, X.; Zhang, L.; Du, H.; Zhang, J.; Li, Y. Y.; Qu, J.; Zhang, W.; Wang, Y.; Bao, S.; Li, Y.; Wu, C.; Liu, H.; Liu, D.; Shao, J.; Peng, X.; Yang, Y.; Liu, Z.; Xiang, Y.; Zhang, F.; Silva, R. M.; Pinkerton, K. E.; Shen, K.; Xiao, H.; Xu, S.; Wong, G. W. K., SARS-CoV-2 Infection in Children. *New England Journal of Medicine* 2020. https://www.nejm.org/doi/full/10.1056/NEJMc2005073

146. (U) Luo, L.; Liu, D.; Liao, X.-I.; Wu, X.-b.; Jing, Q.-I.; Zheng, J.-z.; Liu, F.-h.; Yang, S.-g.; Bi, B.; Li, Z.-h.; Liu, J.-p.; Song, W.-q.; Zhu, W.; Wang, Z.-h.; Zhang, X.-r.; Chen, P.-I.; Liu, H.-m.; Cheng, X.; Cai, M.-c.; Huang, Q.-m.; Yang, P.; Yang, X.-f.; Huang, Z.-g.; Tang, J.-I.; Ma, Y.; Mao, C., Modes of contact and risk of transmission in COVID-19 among close contacts. *medRxiv* **2020**, 2020.03.24.20042606.

https://www.medrxiv.org/content/medrxiv/early/2020/03/26/2020.03.24.20042606.full.pdf

147. (U) Luo, W.; Majumder, M. S.; Liu, D.; Poirier, C.; Mandl, K. D.; Lipsitch, M.; Santillana, M., The role of absolute humidity on transmission rates of the COVID-19 outbreak. *medRxiv* **2020**, 2020.02.12.20022467.

https://www.medrxiv.org/content/medrxiv/early/2020/02/17/2020.02.12.20022467.full.pdf

148. (U) Majumder, M.; Mandl, K., Early transmissibility assessment of a novel coronavirus in Wuhan, China. *SSRN* **2020**. <u>https://papers.ssrn.com/sol3/papers.cfm?abstract\_id=3524675</u>

149. (U) Malik, A. A.; Couzens, C.; Omer, S. B., COVID-19 related social distancing measures and reduction in city mobility. *medRxiv* **2020**, 2020.03.30.20048090.

https://www.medrxiv.org/content/medrxiv/early/2020/04/06/2020.03.30.20048090.full.pdf 150. (U) Mallapaty, S., Coronavirus can infect cats — dogs, not so much. *Nature* **2020**. https://www.nature.com/articles/d41586-020-00984-8

151. (U) Matthay, M. A.; Aldrich, J. M.; Gotts, J. E., Treatment for severe acute respiratory distress syndrome from COVID-19. *The Lancet Respiratory Medicine* **2020**. <u>https://doi.org/10.1016/S2213-2600(20)30127-2</u>

152. (U) Maxmen, A., How blood from coronavirus survivors might save lives. Nature News 2020.

153. (U) Menachery, V. D.; Dinnon, K. H.; Yount, B. L.; McAnarney, E. T.; Gralinski, L. E.; Hale, A.; Graham, R. L.; Scobey, T.; Anthony, S. J.; Wang, L.; Graham, B.; Randell, S. H.; Lipkin, W. I.; Baric, R. S., Trypsin Treatment Unlocks Barrier for Zoonotic Bat Coronavirus Infection. *Journal of Virology* **2020**, *94* (5), e01774-19. https://jvi.asm.org/content/jvi/94/5/e01774-19.full.pdf

154. (U) Mezher, M., FDA Grants First EUA for Blood Purification Device for COVID-19 Patients. *Regulatory Focus* 2020.

155. (U) Ministry for Foreign Affairs, Large scale testing of general population in Iceland underway In *Government of Iceland*, Government of Iceland: 2020.

https://www.government.is/news/article/2020/03/15/Large-scale-testing-of-general-population-in-Iceland-underway/

156. (U) Moriarty, L. F.; Plucinski, M. M.; Marston, B. J. e. a., Public Health Responses fo COVID-19 Outbreaks on Cruise Ships - Worldwide, February - March 2020. *MMWR* **2020**, (ePub: 23 March 2020). <u>https://www.cdc.gov/mmwr/volumes/69/wr/mm6912e3.htm</u>

157. (U) Munster, V. J.; Feldmann, F.; Williamson, B. N.; van Doremalen, N.; Pérez-Pérez, L.; Schulz, J.; Meade-White, K.; Okumura, A.; Callison, J.; Brumbaugh, B.; Avanzato, V. A.; Rosenke, R.; Hanley, P. W.; Saturday, G.; Scott, D.; Fischer, E. R.; de Wit, E., Respiratory disease and virus shedding in rhesus macaques inoculated with SARS-CoV-2. *bioRxiv* **2020**, 2020.03.21.001628.

https://www.biorxiv.org/content/biorxiv/early/2020/03/21/2020.03.21.001628.full.pdf

158. (U) Muoio, D., Scanwell Health, myLAB Box unveil more at-home COVID-19 testing services. *MobiHealthNews* 20 March, 2020.

159. (U) Nadi, A., An at-home fingerprick blood test may help detect your exposure to coronavirus. *NBC NEWS* 04 April, 2020.

160. (U) NIH, NIH clinical trial of remdesivir to treat COVID-19 begins <u>https://www.nih.gov/news-events/news-releases/nih-clinical-trial-remdesivir-treat-covid-19-begins</u>.

161. (U) Okba, N.; Müller, M.; Li, W.; Wang, C.; GeurtsvanKessel, C.; Corman, V.; Lamers, M.; Sikkema, R.; de Bruin, E.; Chandler, F., Severe Acute Respiratory Syndrome Coronavirus 2-Specific Antibody Responses in Coronavirus Disease 2019 Patients. *Emerging infectious diseases* **2020**, *26* (7).

162. (U) Onder, G.; Rezza, G.; Brusaferro, S., Case-Fatality Rate and Characteristics of Patients Dying in Relation to COVID-19 in Italy. *JAMA* **2020**. <u>https://doi.org/10.1001/jama.2020.4683</u>

163. (U) Ong, S. W. X.; Tan, Y. K.; Chia, P. Y.; Lee, T. H.; Ng, O. T.; Wong, M. S. Y.; Marimuthu, K., Air, Surface Environmental, and Personal Protective Equipment Contamination by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) From a Symptomatic Patient. *Jama* **2020**.

https://jamanetwork.com/journals/jama/articlepdf/2762692/jama ong 2020 ld 200016.pdf

164. (U) Ortega, J. T.; Serrano, M. L.; Pujol, F. H.; Rangel, H. R., Role of changes in SARS-CoV-2 spike protein in the interaction with the human ACE2 receptor: An in silico analysis. *EXCLI journal* **2020**, *19*, 410-417. <u>https://pubmed.ncbi.nlm.nih.gov/32210742</u>

### https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7081066/

165. (U) Pan, A.; Liu, L.; Wang, C.; Guo, H.; Hao, X.; Wang, Q.; Huang, J.; He, N.; Yu, H.; Lin, X., Association of Public Health Interventions With the Epidemiology of the COVID-19 Outbreak in Wuhan, China. *JAMA* **2020**.

166. (U) Pan, F.; Ye, T.; Sun, P.; Gui, S.; Liang, B.; Li, L.; Zheng, D.; Wang, J.; Hesketh, R. L.; Yang, L.; Zheng, C., Time Course of Lung Changes On Chest CT During Recovery From 2019 Novel Coronavirus (COVID-19) Pneumonia. *Radiology 0* (0), 200370. <u>https://pubs.rsna.org/doi/abs/10.1148/radiol.2020200370</u> 167. (U) Pan, L.; Mu, M.; Yang, P.; Sun, Y.; Wang, R.; Yan, J.; Li, P.; Hu, B.; Wang, J.; Hu, C.; Jin, Y.; Niu, X.; Ping, R.; Du, Y.; Li, T.; Xu, G.; Hu, Q.; Tu, L., Clinical characteristics of COVID-19 patients with digestive symptoms in Hubei, China: a descriptive, cross-sectional, multicenter study. *The American Journal of Gastroenterology* **2020**.

https://journals.lww.com/ajg/Documents/COVID Digestive Symptoms AJG Preproof.pdf

168. (U) Park, A., An At-Home Coronavirus Test May Be on the Way in the U.S. *TIME* 25 March, 2020. 169. (U) Park, S. W.; Champredon, D.; Earn, D. J. D.; Li, M.; Weitz, J. S.; Grenfell, B. T.; Dushoff, J., Reconciling early-outbreak preliminary estimates of the basic reproductive number and its uncertainty: a new framework and applications to the novel coronavirus (2019-nCoV) outbreak. **2020**, 1-13. 170. (U) Prem, K.; Liu, Y.; Russell, T. W.; Kucharski, A. J.; Eggo, R. M.; Davies, N.; Flasche, S.; Clifford, S.; Pearson, C. A. B.; Munday, J. D.; Abbott, S.; Gibbs, H.; Rosello, A.; Quilty, B. J.; Jombart, T.; Sun, F.; Diamond, C.; Gimma, A.; van Zandvoort, K.; Funk, S.; Jarvis, C. I.; Edmunds, W. J.; Bosse, N. I.; Hellewell, J.; Jit, M.; Klepac, P., The effect of control strategies to reduce social mixing on outcomes of the COVID-19 epidemic in Wuhan, China: a modelling study. *The Lancet Public Health* **2020**.

https://doi.org/10.1016/S2468-2667(20)30073-6

171. (U) Pyankov, O. V.; Bodnev, S. A.; Pyankova, O. G.; Agranovski, I. E., Survival of aerosolized coronavirus in the ambient air. *Journal of Aerosol Science* **2018**, *115*, 158-163.

http://www.sciencedirect.com/science/article/pii/S0021850217302239

172. (U) Qiu, H.; Wu, J.; Hong, L.; Luo, Y.; Song, Q.; Chen, D., Clinical and epidemiological features of 36 children with coronavirus disease 2019 (COVID-19) in Zhejiang, China: an observational cohort study. *The Lancet Infectious Diseases*. <u>https://doi.org/10.1016/S1473-3099(20)30198-5</u>

173. (U) Rabenau, H.; Kampf, G.; Cinatl, J.; Doerr, H., Efficacy of various disinfectants against SARS coronavirus. *Journal of Hospital Infection* **2005**, *61* (2), 107-111.

https://www.sciencedirect.com/science/article/pii/S0195670105000447

174. (U) Rabenau, H. F.; Cinatl, J.; Morgenstern, B.; Bauer, G.; Preiser, W.; Doerr, H. W., Stability and inactivation of SARS coronavirus. *Med Microbiol Immunol* **2005**, *194* (1-2), 1-6.

https://link.springer.com/content/pdf/10.1007/s00430-004-0219-0.pdf

175. (U) Rambaut, A., Phylodynamic analysis of nCoV-2019 genomes - 27-Jan-2020.

http://virological.org/t/phylodynamic-analysis-of-ncov-2019-genomes-27-jan-2020/353.

176. (U) Rapid Expert Consultation, *Rapid Expert Consultation Update on SARS-CoV-2 Surface Stability and Incubation for the COVID-19 Pandemic (March 27, 2020)*. The National Academies Press: Washington, DC, 2020. https://www.nap.edu/read/25763/chapter/1

177. (U) Regalado, A., Blood tests show 14% of people are now immune to covid-19 in one town in Germany. *Technology Review* 2020.

178. (U) Remuzzi, A.; Remuzzi, G., COVID-19 and Italy: what next? *The Lancet* **2020**. <u>https://doi.org/10.1016/S0140-6736(20)30627-9</u>

179. (U) Ren, X.; Liu, Y.; Chen, H.; Liu, W.; Guo, Z.; Chen, C.; Zhou, J.; Xiao, Q.; Jiang, G.-M.; Shan, H., Application and Optimization of RT-PCR in Diagnosis of SARS-CoV-2 Infection. *medRxiv* **2020**.

180. (U) Rengasamy, S.; Eimer, B.; Shaffer, R. E., Simple respiratory protection--evaluation of the filtration performance of cloth masks and common fabric materials against 20-1000 nm size particles. *Ann Occup Hyg* **2010**, *54* (7), 789-98. <u>https://www.ncbi.nlm.nih.gov/pubmed/20584862</u>

181. (U) Richter, W.; Hofacre, K.; Willenberg, Z., *Final Report for the Bioquell Hydrogen Peroxide Vapor (HPV) Decontamination for Reuse of N95 Respirators*; Battelle Memorial Institute: 2016. http://wayback.archive-

it.org/7993/20170113034232/http://www.fda.gov/downloads/EmergencyPreparedness/Counterterrori sm/MedicalCountermeasures/MCMRegulatoryScience/UCM516998.pdf

182. (U) Riou, J.; Althaus, C. L., Pattern of early human-to-human transmission of Wuhan 2019 novel coronavirus (2019-nCoV), December 2019 to January 2020. *Eurosurveillance* **2020**, *25* (4), 2000058. https://www.eurosurveillance.org/content/10.2807/1560-7917.ES.2020.25.4.2000058

183. (U) Roberts, M., Coronavirus: US volunteers test first vaccine. BBC 2020.

184. (U) Robertson, D., nCoV's relationship to bat coronaviruses & recombination signals (no snakes) 2020. <u>http://virological.org/t/ncovs-relationship-to-bat-coronaviruses-recombination-signals-no-snakes/331</u>

185. (U) Rockx, B.; Kuiken, T.; Herfst, S.; Bestebroer, T.; Lamers, M.; de Meulder, D.; van Amerongen, G.; van de Brand, J.; Okba, N.; Schipper, D.; van Run, P.; Leijten, L.; Verschoor, E.; Verstrepen, B.;

Langermans, J.; Drosten, C.; Fentener van Vlissingen, M.; Fouchier, R.; de Swart, R. L.; Koopmans, M.; Haagmans, B., Comparative Pathogenesis Of COVID-19, MERS And SARS In A Non-Human Primate Model. *bioRxiv* **2020**, 2020.03.17.995639.

https://www.biorxiv.org/content/biorxiv/early/2020/03/17/2020.03.17.995639.full.pdf

186. (U) Rothe, C.; Schunk, M.; Sothmann, P.; Bretzel, G.; Froeschl, G.; Wallrauch, C.; Zimmer, T.; Thiel, V.; Janke, C.; Guggemos, W.; Seilmaier, M.; Drosten, C.; Vollmar, P.; Zwirglmaier, K.; Zange, S.; Wölfel, R.; Hoelscher, M., Transmission of 2019-nCoV Infection from an Asymptomatic Contact in Germany. *New England Journal of Medicine* **2020**. <u>https://www.nejm.org/doi/full/10.1056/NEJMc2001468</u> https://www.nejm.org/doi/10.1056/NEJMc2001468

187. (U) Ruan, Q.; Yang, K.; Wang, W.; Jiang, L.; Song, J., Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China. *Intensive Care Medicine* **2020**. <u>https://doi.org/10.1007/s00134-020-05991-x</u>

188. (U) Saknimit, M.; Inatsuki, I.; Sugiyama, Y.; Yagami, K., Virucidal efficacy of physico-chemical treatments against coronaviruses and parvoviruses of laboratory animals. *Jikken Dobutsu* **1988**, *37* (3), 341-5. <u>https://www.jstage.jst.go.jp/article/expanim1978/37/3/37\_3\_341/\_pdf</u>

189. (U) Santarpia, J. L.; Rivera, D. N.; Herrera, V.; Morwitzer, M. J.; Creager, H.; Santarpia, G. W.; Crown, K. K.; Brett-Major, D.; Schnaubelt, E.; Broadhurst, M. J.; Lawler, J. V.; Reid, S. P.; Lowe, J. J., Transmission Potential of SARS-CoV-2 in Viral Shedding Observed at the University of Nebraska Medical Center. *medRxiv* **2020**, 2020.03.23.20039446.

https://www.medrxiv.org/content/medrxiv/early/2020/03/26/2020.03.23.20039446.1.full.pdf 190. (U) Schnirring, L., New coronavirus infects health workers, spreads to Korea.

http://www.cidrap.umn.edu/news-perspective/2020/01/new-coronavirus-infects-health-workersspreads-korea.

191. (U) Schwartz, D. A., An analysis of 38 pregnant women with COVID-19, their newborn infants, and maternal-fetal transmission of SARS-CoV-2: maternal coronavirus infections and pregnancy outcomes. *Archives of Pathology & Laboratory Medicine* **2020**.

192. (U) Security, J. C. f. H., 2019-nCoV resources and updates on the emerging novel coronavirus. **2020**. <u>http://www.centerforhealthsecurity.org/resources/2019-nCoV/</u>

193. (U) Sheahan, T. P.; Sims, A. C.; Graham, R. L.; Menachery, V. D.; Gralinski, L. E.; Case, J. B.; Leist, S. R.; Pyrc, K.; Feng, J. Y.; Trantcheva, I.; Bannister, R.; Park, Y.; Babusis, D.; Clarke, M. O.; Mackman, R. L.; Spahn, J. E.; Palmiotti, C. A.; Siegel, D.; Ray, A. S.; Cihlar, T.; Jordan, R.; Denison, M. R.; Baric, R. S., Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses. *Sci Transl Med* **2017**, *9* (396). https://stm.sciencemag.org/content/scitransmed/9/396/eaal3653.full.pdf

194. (U) Sheahan, T. P.; Sims, A. C.; Zhou, S.; Graham, R. L.; Pruijssers, A. J.; Agostini, M. L.; Leist, S. R.; Schäfer, A.; Dinnon, K. H.; Stevens, L. J.; Chappell, J. D.; Lu, X.; Hughes, T. M.; George, A. S.; Hill, C. S.; Montgomery, S. A.; Brown, A. J.; Bluemling, G. R.; Natchus, M. G.; Saindane, M.; Kolykhalov, A. A.; Painter, G.; Harcourt, J.; Tamin, A.; Thornburg, N. J.; Swanstrom, R.; Denison, M. R.; Baric, R. S., An orally bioavailable broad-spectrum antiviral inhibits SARS-CoV-2 in human airway epithelial cell cultures and multiple coronaviruses in mice. Science Translational Medicine 2020, eabb5883.

http://stm.sciencemag.org/content/early/2020/04/03/scitranslmed.abb5883.abstract

195. (U) Shen, C.; Wang, Z.; Zhao, F.; Yang, Y.; Li, J.; Yuan, J.; Wang, F.; Li, D.; Yang, M.; Xing, L.; Wei, J.; Xiao, H.; Yang, Y.; Qu, J.; Qing, L.; Chen, L.; Xu, Z.; Peng, L.; Li, Y.; Zheng, H.; Chen, F.; Huang, K.; Jiang, Y.; Liu, D.; Zhang, Z.; Liu, Y.; Liu, L., Treatment of 5 Critically III Patients With COVID-19 With Convalescent Plasma. JAMA 2020. https://doi.org/10.1001/jama.2020.4783

196. (U) Sheridan, C., Coronavirus and the race to distribute reliable diagnostics. https://www.nature.com/articles/d41587-020-00002-2.

197. (U) Shi, J.; Wen, Z.; Zhong, G.; Yang, H.; Wang, C.; Huang, B.; Liu, R.; He, X.; Shuai, L.; Sun, Z.; Zhao, Y.; Liu, P.; Liang, L.; Cui, P.; Wang, J.; Zhang, X.; Guan, Y.; Tan, W.; Wu, G.; Chen, H.; Bu, Z., Susceptibility of ferrets, cats, dogs, and other domesticated animals to SARS–coronavirus 2. Science 2020, eabb7015. https://science.sciencemag.org/content/sci/early/2020/04/07/science.abb7015.full.pdf

198. (U) Shi, S.; Qin, M.; Shen, B.; Cai, Y.; Liu, T.; Yang, F.; Gong, W.; Liu, X.; Liang, J.; Zhao, Q.; Huang, H.; Yang, B.; Huang, C., Association of Cardiac Injury With Mortality in Hospitalized Patients With COVID-19 in Wuhan, China. JAMA Cardiology 2020. https://doi.org/10.1001/jamacardio.2020.0950

199. (U) Shi, W.; Peng, X.; Liu, T.; Cheng, Z.; Lu, H.; Yang, S.; Zhang, J.; Li, F.; Wang, M.; Zhang, X.; Gao, Y.; Shi, Y.; Zhang, Z.; Shan, F., Deep Learning-Based Quantitative Computed Tomography Model in Predicting the Severity of COVID-19: A Retrospective Study in 196 Patients. SSRN 2020. https://papers.ssrn.com/sol3/papers.cfm?abstract\_id=3546089

200. (U) Su, Y. C.; Anderson, D. E.; Young, B. E.; Zhu, F.; Linster, M.; Kalimuddin, S.; Low, J. G.; Yan, Z.; Jayakumar, J.; Sun, L.; Yan, G. Z.; Mendenhall, I. H.; Leo, Y.-S.; Lye, D. C.; Wang, L.-F.; Smith, G. J., Discovery of a 382-nt deletion during the early evolution of SARS-CoV-2. *bioRxiv* 2020, 2020.03.11.987222.

https://www.biorxiv.org/content/biorxiv/early/2020/03/12/2020.03.11.987222.full.pdf

201. (U) ter Meulen, J.; van den Brink, E. N.; Poon, L. L.; Marissen, W. E.; Leung, C. S.; Cox, F.; Cheung, C. Y.; Bakker, A. Q.; Bogaards, J. A.; van Deventer, E.; Preiser, W.; Doerr, H. W.; Chow, V. T.; de Kruif, J.; Peiris, J. S.; Goudsmit, J., Human monoclonal antibody combination against SARS coronavirus: synergy and coverage of escape mutants. PLoS Med 2006, 3 (7), e237.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1483912/pdf/pmed.0030237.pdf

202. (U) Terry, M., Vir Biotech IDs Two Antibodies That Could Be Effective in Preventing and Treating COVID-19. BioSpace: 2020. https://www.biospace.com/article/vir-biotechnology-ids-2-monoclonalantibodies-against-the-covid-19-coronavirus/

203. (U) The Novel Coronavirus Pneumonia Emergency Response Epidemiology, T., The Epidemiological Characteristics of an Outbreak of 2019 Novel Coronavirus Diseases (COVID-19) — China, 2020. China CDC Weekly 2020, 2, 1-10. http://weekly.chinacdc.cn//article/id/e53946e2-c6c4-41e9-9a9bfea8db1a8f51

204. (U) Thevarajan, I.; Nguyen, T. H. O.; Koutsakos, M.; Druce, J.; Caly, L.; van de Sandt, C. E.; Jia, X.; Nicholson, S.; Catton, M.; Cowie, B.; Tong, S. Y. C.; Lewin, S. R.; Kedzierska, K., Breadth of concomitant immune responses prior to patient recovery: a case report of non-severe COVID-19. Nature Medicine 2020. https://doi.org/10.1038/s41591-020-0819-2

205. (U) Thomas, P. R.; Karriker, L. A.; Ramirez, A.; Zhang, J.; Ellingson, J. S.; Crawford, K. K.; Bates, J. L.; Hammen, K. J.; Holtkamp, D. J., Evaluation of time and temperature sufficient to inactivate porcine

epidemic diarrhea virus in swine feces on metal surfaces. *Journal of Swine Health and Production* **2015**, *23* (2), 84.

206. (U) Thomas, P. R.; Ramirez, A.; Zhang, J.; Ellingson, J. S.; Myers, J. N., Methods for inactivating PEDV in Hog Trailers. *Animal Industry Report* **2015**, *661* (1), 91.

207. (U) To, K. K.-W.; Tsang, O. T.-Y.; Yip, C. C.-Y.; Chan, K.-H.; Wu, T.-C.; Chan, J. M.-C.; Leung, W.-S.; Chik, T. S.-H.; Choi, C. Y.-C.; Kandamby, D. H.; Lung, D. C.; Tam, A. R.; Poon, R. W.-S.; Fung, A. Y.-F.; Hung, I. F.-N.; Cheng, V. C.-C.; Chan, J. F.-W.; Yuen, K.-Y., Consistent Detection of 2019 Novel Coronavirus in Saliva. *Clinical Infectious Diseases* **2020**. <u>https://academic.oup.com/cid/advance-</u> article/doi/10.1093/cid/ciaa149/5734265

208. (U) Toner, E., *Interim Estimate of the US PPE Needs for COVID-19*; Johns Hopkins Center for Health Security: 2020. <u>https://www.centerforhealthsecurity.org/resources/COVID-19/PPE/PPE-estimate.pdf</u> 209. (U) van der Sande, M.; Teunis, P.; Sabel, R., Professional and Home-Made Face Masks Reduce Exposure to Respiratory Infections among the General Population. *Plos One* **2008**, *3* (7). <Go to ISI>://WOS:000264065800020

210. (U) van Doremalen, N.; Bushmaker, T.; Morris, D. H.; Holbrook, M. G.; Gamble, A.; Williamson, B. N.; Tamin, A.; Harcourt, J. L.; Thornburg, N. J.; Gerber, S. I.; Lloyd-Smith, J. O.; de Wit, E.; Munster, V. J., Aerosol and Surface Stability of SARS-CoV-2 as Compared with SARS-CoV-1. *New England Journal of Medicine* **2020**. <u>https://doi.org/10.1056/NEJMc2004973</u>

211. (U) van Doremalen, N.; Bushmaker, T.; Munster, V. J., Stability of Middle East respiratory syndrome coronavirus (MERS-CoV) under different environmental conditions. *Euro Surveill* **2013**, *18* (38).

212. (U) Verdict, Cepheid to develop automated molecular test for coronavirus. Verdict Medical Devices: 2020. <u>https://www.medicaldevice-network.com/news/cepheid-automated-test-coronavirus/</u>

213. (U) Wan, Y.; Shang, J.; Graham, R.; Baric, R. S.; Li, F., Receptor recognition by novel coronavirus from Wuhan: An analysis based on decade-long structural studies of SARS. *Journal of Virology* **2020**, JVI.00127-20. <u>https://jvi.asm.org/content/jvi/early/2020/01/23/JVI.00127-20.full.pdf</u>

214. (U) Wang, D.; Hu, B.; Hu, C.; Zhu, F.; Liu, X.; Zhang, J.; Wang, B.; Xiang, H.; Cheng, Z.; Xiong, Y.; Zhao, Y.; Li, Y.; Wang, X.; Peng, Z., Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus–Infected Pneumonia in Wuhan, China. *JAMA* **2020**.

https://doi.org/10.1001/jama.2020.1585

https://jamanetwork.com/journals/jama/articlepdf/2761044/jama\_wang\_2020\_oi\_200019.pdf 215. (U) Wang, W.; Xu, Y.; Gao, R.; Lu, R.; Han, K.; Wu, G.; Tan, W., Detection of SARS-CoV-2 in Different Types of Clinical Specimens. *JAMA* **2020**. <u>https://doi.org/10.1001/jama.2020.3786</u>

216. (U) Wang, Y.; Liu, Y.; Liu, L.; Wang, X.; Luo, N.; Ling, L., Clinical outcome of 55 asymptomatic cases at the time of hospital admission infected with SARS-Coronavirus-2 in Shenzhen, China. *The Journal of infectious diseases* **2020**.

217. (U) Watson, C.; Cicero, A.; Blumenstock, J.; Fraser, M., *A National Plan to Enable Comprehensive COVID-19 Case Finding and Contact*; Johns Hopkins Center for Health Security: 2020.

<u>https://www.centerforhealthsecurity.org/our-work/pubs\_archive/pubs-pdfs/2020/a-national-plan-to-</u> enable-comprehensive-COVID-19-case-finding-and-contact-tracing-in-the-US.pdf

218. (U) WCS, A Tiger at Bronx Zoo Tests Positive for COVID-19; The Tiger and the Zoo's Other Cats Are Doing Well at This Time. <u>https://newsroom.wcs.org/News-</u>

<u>Releases/articleType/ArticleView/articleId/14010/A-Tiger-at-Bronx-Zoo-Tests-Positive-for-COVID-19-</u> The-Tiger-and-the-Zoos-Other-Cats-Are-Doing-Well-at-This-Time.aspx (accessed April 6, 2020).

219. (U) Wei, W. E.; Li, Z.; Chiew, C. J.; Yong, S. E.; Toh, M. P.; Lee, V. J., Presymptomatic transmission of SARS-CoV-2 - Singapore, January 23 - March 16, 2020. *Morbidity and Mortality Weekly Report* **2020**, *ePub* (1 April 2020). <u>https://www.cdc.gov/mmwr/volumes/69/wr/mm6914e1.htm</u>

220. (U) Weston, S.; Haupt, R.; Logue, J.; Matthews, K.; Frieman, M. B., FDA approved drugs with broad anti-coronaviral activity inhibit SARS-CoV-2 <em>in vitro</em>. *bioRxiv* **2020**, 2020.03.25.008482. <u>https://www.biorxiv.org/content/biorxiv/early/2020/03/27/2020.03.25.008482.full.pdf</u>

221. (U) Wetsman, N., FDA authorizes first antibody-based test for COVID-19. *The Verge* 2 April, 2020. 222. (U) WHO, Diagnostic detection of Wuhan coronavirus 2019 by real-time RTPCR -Protocol and preliminary evaluation as of Jan 13, 2020. <u>https://www.who.int/docs/default-source/coronaviruse/wuhan-virus-assay-</u>

v1991527e5122341d99287a1b17c111902.pdf?sfvrsn=d381fc88 2 (accessed 01/26/2020).

223. (U) WHO, Infection prevention and control during health care when novel coronavirus (nCoV) infection is suspected; 2020. <u>https://www.who.int/publications-detail/infection-prevention-and-control-during-health-care-when-novel-coronavirus-(ncov)-infection-is-suspected-20200125</u>

224. (U) WHO, Laboratory testing for 2019 novel coronavirus (2019-nCoV) in suspected human cases. 225. (U) WHO, *Modes of transmission of virus causing COVID-19: implications for IPC precaution recommendations*; World Health Organization: 2020. https://www.who.int/news-

<u>room/commentaries/detail/modes-of-transmission-of-virus-causing-covid-19-implications-for-ipc-</u> precaution-recommendations

226. (U) WHO, Novel Coronavirus (2019-nCoV) Situation Report-5 25 January 2020. <u>https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200125-sitrep-5-2019-ncov.pdf?sfvrsn=429b143d\_4</u>.

227. (U) WHO, Novel Coronavirus (2019-nCoV) technical guidance: Laboratory testing for 2019-nCoV in humans. <u>https://www.who.int/emergencies/diseases/novel-coronavirus-2019/technical-guidance/laboratory-guidance</u>.

228. (U) Wölfel, R.; Corman, V. M.; Guggemos, W.; Seilmaier, M.; Zange, S.; Müller, M. A.; Niemeyer, D.; Jones, T. C.; Vollmar, P.; Rothe, C.; Hoelscher, M.; Bleicker, T.; Brünink, S.; Schneider, J.; Ehmann, R.; Zwirglmaier, K.; Drosten, C.; Wendtner, C., Virological assessment of hospitalized patients with COVID-2019. *Nature* **2020**. <u>https://doi.org/10.1038/s41586-020-2196-x</u>

229. (U) Wolff, M. H.; Sattar, S. A.; Adegbunrin, O.; Tetro, J., Environmental survival and microbicide inactivation of coronaviruses. In *Coronaviruses with special emphasis on first insights concerning SARS*, Springer: 2005; pp 201-212.

230. (U) Wong, M. C.; Javornik Cregeen, S. J.; Ajami, N. J.; Petrosino, J. F., Evidence of recombination in coronaviruses implicating pangolin origins of nCoV-2019. *bioRxiv* **2020**, 2020.02.07.939207. https://www.biorxiv.org/content/biorxiv/early/2020/02/13/2020.02.07.939207.full.pdf

231. (U) Wrapp, D.; Wang, N.; Corbett, K. S.; Goldsmith, J. A.; Hsieh, C.-L.; Abiona, O.; Graham, B. S.; McLellan, J. S., Cryo-EM Structure of the 2019-nCoV Spike in the Prefusion Conformation. *bioRxiv* **2020**, 2020.02.11.944462.

https://www.biorxiv.org/content/biorxiv/early/2020/02/15/2020.02.11.944462.full.pdf

232. (U) Wu, F.; Wang, A.; Liu, M.; Wang, Q.; Chen, J.; Xia, S.; Ling, Y.; Zhang, Y.; Xun, J.; Lu, L.; Jiang, S.; Lu, H.; Wen, Y.; Huang, J., Neutralizing antibody responses to SARS-CoV-2 in a COVID-19 recovered patient cohort and their implications. *medRxiv* **2020**, 2020.03.30.20047365.

https://www.medrxiv.org/content/medrxiv/early/2020/04/06/2020.03.30.20047365.full.pdf

233. (U) Wu, J. T.; Leung, K.; Leung, G. M., Nowcasting and forecasting the potential domestic and international spread of the 2019-nCoV outbreak originating in Wuhan, China: a modelling study. *The Lancet* **2020**. <u>https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)30260-9/fulltext</u>

234. (U) Wu, L.-P.; Wang, N.-C.; Chang, Y.-H.; Tian, X.-Y.; Na, D.-Y.; Zhang, L.-Y.; Zheng, L.; Lan, T.; Wang, L.-F.; Liang, G.-D., Duration of antibody responses after severe acute respiratory syndrome. *Emerging infectious diseases* **2007**, *13* (10), 1562.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2851497/pdf/07-0576\_finalD.pdf

235. (U) Wu, P.; Duan, F.; Luo, C.; Liu, Q.; Qu, X.; Liang, L.; Wu, K., Characteristics of Ocular Findings of Patients With Coronavirus Disease 2019 (COVID-19) in Hubei Province, China. *JAMA Ophthalmology* **2020**. <u>https://doi.org/10.1001/jamaophthalmol.2020.1291</u>

236. (U) Xinhua, China detects large quantity of novel coronavirus at Wuhan seafood market <u>http://www.xinhuanet.com/english/2020-01/27/c 138735677.htm</u>.

237. (U) Xu, X.; Han, M.; Li, T.; Sun, W.; Wang, D.; Fu, B.; Zhou, Y.; Zheng, X.; Yang, Y.; Li, X.; Zhang, X.; Pan, A.; Wei, H., Effective Treatment of Severe COVID-19 Patients with Tocilizumab. *ChinaXiv* **2020**. <u>http://chinaxiv.org/abs/202003.00026</u>

238. (U) Xu, Z.; Shi, L.; Wang, Y.; Zhang, J.; Huang, L.; Zhang, C.; Liu, S.; Zhao, P.; Liu, H.; Zhu, L.; Tai, Y.; Bai, C.; Gao, T.; Song, J.; Xia, P.; Dong, J.; Zhao, J.; Wang, F.-S., Pathological findings of COVID-19 associated with acute respiratory distress syndrome. *The Lancet Respiratory Medicine*.

https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)30260-9/fulltext

239. (U) Xue, K. S.; Bloom, J. D., Reconciling disparate estimates of viral genetic diversity during human influenza infections. *Nature Genetics* **2019**, *51* (9), 1298-1301. <u>https://doi.org/10.1038/s41588-019-0349-3</u>

240. (U) Yang, H.; Wang, C.; Poon, L., Novel coronavirus infection and pregnancy. *Ultrasound in Obstetrics & Gynecology* **2020**.

241. (U) Yang, P.; Qi, J.; Zhang, S.; Bi, G.; Wang, X.; Yang, Y.; Sheng, B.; Mao, X., Feasibility of Controlling COVID-19 Outbreaks in the UK by Rolling Interventions. *medRxiv* **2020**, 2020.04.05.20054429. https://www.medrxiv.org/content/medrxiv/early/2020/04/07/2020.04.05.20054429.full.pdf

242. (U) Yoon, I.-K.; Kim, J. H., First clinical trial of a MERS coronavirus DNA vaccine. *The Lancet Infectious Diseases* **2019**, *19* (9), 924-925. <u>https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(19)30397-4/fulltext</u>

243. (U) Yu, W.-B.; Tang, G.-D.; Zhang, L.; Corlett, R. T., Decoding evolution and transmissions of novel pneumonia coronavirus using the whole genomic data. *ChinaXiv* **2020**. <u>http://www.chinaxiv.org/abs/202002.00033</u>

244. (U) Zhang, Q.; Zhang, H.; Huang, K.; Yang, Y.; Hui, X.; Gao, J.; He, X.; Li, C.; Gong, W.; Zhang, Y.; Peng, C.; Gao, X.; Chen, H.; Zou, Z.; Shi, Z.; Jin, M., SARS-CoV-2 neutralizing serum antibodies in cats: a serological investigation. *bioRxiv* **2020**, 2020.04.01.021196.

http://biorxiv.org/content/early/2020/04/03/2020.04.01.021196.abstract

245. (U) Zhao; Musa; Lin; Ran; Yang; Wang; Lou; Yang; Gao; He; Wang, Estimating the Unreported Number of Novel Coronavirus (2019-nCoV) Cases in China in the First Half of January 2020: A Data-Driven Modelling Analysis of the Early Outbreak. *Journal of Clinical Medicine* **2020**, *9* (2), 388.

246. (U) Zhao, G.; Jiang, Y.; Qiu, H.; Gao, T.; Zeng, Y.; Guo, Y.; Yu, H.; Li, J.; Kou, Z.; Du, L.; Tan, W.; Jiang, S.; Sun, S.; Zhou, Y., Multi-Organ Damage in Human Dipeptidyl Peptidase 4 Transgenic Mice Infected with Middle East Respiratory Syndrome-Coronavirus. *PLoS One* **2015**, *10* (12), e0145561. <u>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4689477/pdf/pone.0145561.pdf</u>

247. (U) Zhao, J.; Yuan, Q.; Wang, H.; Liu, W.; Liao, X.; Su, Y.; Wang, X.; Yuan, J.; Li, T.; Li, J.; Qian, S.; Hong, C.; Wang, F.; Liu, Y.; Wang, Z.; He, Q.; He, B.; Zhang, T.; Ge, S.; Liu, L.; Zhang, J.; Xia, N.; Zhang, Z., Antibody Responses to SARS-CoV-2 in Patients of Novel Coronavirus Disease 2019. *SSRN* **2020**. <u>https://papers.ssrn.com/sol3/papers.cfm?abstract\_id=3546052#</u>

248. (U) Zhen-Dong, T.; An, T.; Ke-Feng, L.; Peng, L.; Hong-Ling, W.; Jing-Ping, Y.; Yong-Li, Z.; Jian-Bo, Y., Potential Presymptomatic Transmission of SARS-CoV-2, Zhejiang Province, China, 2020. *Emerging Infectious Disease journal* **2020**, *26* (5). <u>https://wwwnc.cdc.gov/eid/article/26/5/20-0198\_article</u> 249. (U) Zhongchu, L., The sixth press conference of "Prevention and Control of New Coronavirus Infected Pneumonia". Hubei Provincial Government: 2020.

http://www.hubei.gov.cn/hbfb/xwfbh/202001/t20200128\_2015591.shtml

250. (U) Zhou, F.; Yu, T.; Du, R.; Fan, G.; Liu, Y.; Liu, Z.; Xiang, J.; Wang, Y.; Song, B.; Gu, X.; Guan, L.; Wei, Y.; Li, H.; Wu, X.; Xu, J.; Tu, S.; Zhang, Y.; Chen, H.; Cao, B., Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. *The Lancet*. https://doi.org/10.1016/S0140-6736(20)30566-3

251. (U) Zhou, P.; Yang, X.-L.; Wang, X.-G.; Hu, B.; Zhang, L.; Zhang, W.; Si, H.-R.; Zhu, Y.; Li, B.; Huang, C.-L.; Chen, H.-D.; Chen, J.; Luo, Y.; Guo, H.; Jiang, R.-D.; Liu, M.-Q.; Chen, Y.; Shen, X.-R.; Wang, X.; Zheng, X.-S.; Zhao, K.; Chen, Q.-J.; Deng, F.; Liu, L.-L.; Yan, B.; Zhan, F.-X.; Wang, Y.-Y.; Xiao, G.; Shi, Z.-L., Discovery of a novel coronavirus associated with the recent pneumonia outbreak in humans and its potential bat origin. *bioRxiv* **2020**, 2020.01.22.914952.

https://www.biorxiv.org/content/biorxiv/early/2020/01/23/2020.01.22.914952.1.full.pdf

252. (U) Zhu, Y.; Chen, Y. Q., On a Statistical Transmission Model in Analysis of the Early Phase of COVID-19 Outbreak. *Statistics in Biosciences* **2020**, 1-17.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7113380/

253. (U) Zou, L.; Ruan, F.; Huang, M.; Liang, L.; Huang, H.; Hong, Z.; Yu, J.; Kang, M.; Song, Y.; Xia, J.; Guo, Q.; Song, T.; He, J.; Yen, H.-L.; Peiris, M.; Wu, J., SARS-CoV-2 Viral Load in Upper Respiratory Specimens of Infected Patients. *New England Journal of Medicine* **2020**. https://www.nejm.org/doi/full/10.1056/NEJMc2001737

